Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
≥,29755998,CrCl,CrCl ≥65.25 mL/min was safe for administration in any of the tested regimens (500 mg or 850 mg up to three times daily or 1000 mg up to twice daily).,Application of a Pharmacokinetic Model of Metformin Clearance in a Population with Acute Myeloid Leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755998/),[ml] / [min],65.25,723,DB00331,Metformin
,26317076,flow rate,"The chromatographic separation was achieved with Thermo Hypurity C18 column (50 mm × 4.6 mm, 5 μ) using a mobile phase composition containing 0.1% v/v formic acid in water and acetonitrile (30:70, v/v) at a flow rate of 0.4 mL/min.","Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317076/),[ml] / [min],0.4,2211,DB00331,Metformin
,26317076,total run time,The total run time was 3.5 min.,"Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317076/),min,3.5,2212,DB00331,Metformin
,23293039,total chromatographic run time,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,8.0,2451,DB00331,Metformin
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,3.0,2452,DB00331,Metformin
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,2.9,2453,DB00331,Metformin
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,6.1,2454,DB00331,Metformin
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,4.9,2455,DB00331,Metformin
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,96.4 to 112.8,2456,DB00331,Metformin
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,102.1 to 104.5,2457,DB00331,Metformin
,27390052,peak sitagliptin concentration,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],167,4877,DB00331,Metformin
,27390052,peak sitagliptin concentration,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],174.1,4878,DB00331,Metformin
,27390052,t<sub>max</sub>,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),h,2.25 - 3,4879,DB00331,Metformin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),h,1.75 - 2.25,4880,DB00331,Metformin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],888.3,4881,DB00331,Metformin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],"1,337",4882,DB00331,Metformin
,27390052,AUC012h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"1,404",4883,DB00331,Metformin
,27390052,AUC012h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"1,374",4884,DB00331,Metformin
,27390052,AUC0-12h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"6,015",4885,DB00331,Metformin
,27390052,AUC0-12h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"8,587",4886,DB00331,Metformin
,27390052,renal clearance,"Approximately 75% sitagliptin and 40% metformin were excreted unchanged in the urine, corresponding to a renal clearance of 17.84 - 18.27 L/h for sitagliptin and 27.11 - 27.94 L/h for metformin.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[l] / [h],17.84 - 18.27,4887,DB00331,Metformin
,27390052,renal clearance,"Approximately 75% sitagliptin and 40% metformin were excreted unchanged in the urine, corresponding to a renal clearance of 17.84 - 18.27 L/h for sitagliptin and 27.11 - 27.94 L/h for metformin.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[l] / [h],27.11 - 27.94,4888,DB00331,Metformin
,33118168,AUC0 - 24h,"The median (25th - 75th interquartile range) AUC0 - 24h , CLrenal , C3 and C10 , were 10 600 (8470-12 500) ng* hr* mL-1 , 29 (24-34) L* hour-1 , 1460 (1180-1770) and 260 (200-330) ng* mL-1 , respectively, which is in agreement with our previous results.",Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118168/),[h·ng] / [ml],10 600,6910,DB00331,Metformin
,33118168,C10,"The median (25th - 75th interquartile range) AUC0 - 24h , CLrenal , C3 and C10 , were 10 600 (8470-12 500) ng* hr* mL-1 , 29 (24-34) L* hour-1 , 1460 (1180-1770) and 260 (200-330) ng* mL-1 , respectively, which is in agreement with our previous results.",Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118168/),[ng] / [ml],260,6911,DB00331,Metformin
,25283698,lag time,"The tablets of the optimized formulation floated on the test medium for more than 24 h with 5 min of floating lag time, and sustained MH release for 12 h via a diffusion-dependent manner; and complete release of PG within 5 min were achieved.",Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25283698/),min,5,8357,DB00331,Metformin
,31339572,m/,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,130.1,9977,DB00331,Metformin
,31339572,m/,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,71.1,9978,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,462.0,9979,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,191.2,9980,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,426.1,9981,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,167.1,9982,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,468.0,9983,DB00331,Metformin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,354.9,9984,DB00331,Metformin
,28544884,flow rate,"Chromatographic separation were carried out on a Acquity UPLC HSS Cyano column (100mm x 2.1mm, 1.8μm) using gradient mobile phase system consisting of 0.1% formic acid and acetonitrile at a flow rate of 0.4mL/min, within a run time of 6min.",A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544884/),[ml] / [min],0.4,10485,DB00331,Metformin
,28544884,run time,"Chromatographic separation were carried out on a Acquity UPLC HSS Cyano column (100mm x 2.1mm, 1.8μm) using gradient mobile phase system consisting of 0.1% formic acid and acetonitrile at a flow rate of 0.4mL/min, within a run time of 6min.",A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544884/),min,6,10486,DB00331,Metformin
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.33,12391,DB00331,Metformin
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.29,12392,DB00331,Metformin
,17221919,m,"The precursor-product ion combinations of m/z 130 --> 71, 446 --> 321, 206 --> 60 and 324 --> 127 were used to quantify I, II, III and IV, respectively.",Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221919/),,130,14738,DB00331,Metformin
,18372428,clearance (CL/F),"Population mean estimates (relative standard error [RSE]) of clearance (CL/F) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively.",Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372428/),[l] / [h],79.0,15645,DB00331,Metformin
,18372428,volume of distribution,"Population mean estimates (relative standard error [RSE]) of clearance (CL/F) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively.",Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372428/),l,648,15646,DB00331,Metformin
,18372428,slope coefficient (,An empirical linear model was used to describe a slight progressive increase in fasting lactic acid during metformin treatment with an estimated slope coefficient (RSE) of 0.0005 mM.mL.ng(-1) (38.1%).,Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372428/),[mM·ml] / [ng],0.0005,15647,DB00331,Metformin
,27407018,apparent clearance (CL/F),"Mean population apparent clearance (CL/F) was 68.1 L/h, and mean apparent volume of distribution (V/F) was 28.8 L.",Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27407018/),[l] / [h],68.1,16983,DB00331,Metformin
,27407018,apparent volume of distribution (V/F),"Mean population apparent clearance (CL/F) was 68.1 L/h, and mean apparent volume of distribution (V/F) was 28.8 L.",Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27407018/),l,28.8,16984,DB00331,Metformin
,27569291,AUC0-∞,"When metformin (8.0 mg/kg) was intravenously administered to male Oct3+/+ and Oct3-/- mice, AUC0-∞ of metformin was evaluated to be 659 ± 133 μg h/mL and 734 ± 213 μg h/mL, respectively.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),[h·μg] / [ml],659,18005,DB00331,Metformin
,27569291,AUC0-∞,"When metformin (8.0 mg/kg) was intravenously administered to male Oct3+/+ and Oct3-/- mice, AUC0-∞ of metformin was evaluated to be 659 ± 133 μg h/mL and 734 ± 213 μg h/mL, respectively.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),[h·μg] / [ml],734,18006,DB00331,Metformin
,27569291,AUC0-∞,"In the case of orally administered metformin (15 mg/kg), AUC0-∞ was 578 ± 158 μg h/mL and 449 ± 101 μg h/mL in Oct3+/+ and Oct3-/- mice, respectively.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),[h·μg] / [ml],578,18007,DB00331,Metformin
,27569291,AUC0-∞,"In the case of orally administered metformin (15 mg/kg), AUC0-∞ was 578 ± 158 μg h/mL and 449 ± 101 μg h/mL in Oct3+/+ and Oct3-/- mice, respectively.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),[h·μg] / [ml],449,18008,DB00331,Metformin
,27569291,absolute bioavailability (F),"Based on these pharmacokinetic parameters, absolute bioavailability (F) of metformin in Oct3+/+ mice was evaluated as 46.8%, and it was significantly decreased to 32.6% in Oct3-/- mice.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),%,46.8,18009,DB00331,Metformin
,27569291,absolute bioavailability (F),"Based on these pharmacokinetic parameters, absolute bioavailability (F) of metformin in Oct3+/+ mice was evaluated as 46.8%, and it was significantly decreased to 32.6% in Oct3-/- mice.",Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569291/),%,32.6,18010,DB00331,Metformin
,22380769,apparent clearance,"Population mean estimates (relative standard error, RSE) of apparent clearance, apparent volume of distribution and the absorption rate constant were 52.6 l h(-1) (4.18%), 113 l (56.6%) and 0.41 h(-1) , respectively.",Population PK/PD analysis of metformin using the signal transduction model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380769/),[l] / [h],52.6,18114,DB00331,Metformin
,22380769,apparent volume of distribution,"Population mean estimates (relative standard error, RSE) of apparent clearance, apparent volume of distribution and the absorption rate constant were 52.6 l h(-1) (4.18%), 113 l (56.6%) and 0.41 h(-1) , respectively.",Population PK/PD analysis of metformin using the signal transduction model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380769/),l,113,18115,DB00331,Metformin
,22380769,absorption rate constant,"Population mean estimates (relative standard error, RSE) of apparent clearance, apparent volume of distribution and the absorption rate constant were 52.6 l h(-1) (4.18%), 113 l (56.6%) and 0.41 h(-1) , respectively.",Population PK/PD analysis of metformin using the signal transduction model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380769/),1/[h],0.41,18116,DB00331,Metformin
,22380769,efficacy,"The population means for efficacy, potency, transit time and the Hill coefficient were estimated to be 19.8 (3.17%), 3.68 µg ml(-1) (3.89%), 0.5 h (2.89%) and 0.547 (9.05%), respectively.",Population PK/PD analysis of metformin using the signal transduction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380769/),,19.8,18117,DB00331,Metformin
,22380769,Hill coefficient,"The population means for efficacy, potency, transit time and the Hill coefficient were estimated to be 19.8 (3.17%), 3.68 µg ml(-1) (3.89%), 0.5 h (2.89%) and 0.547 (9.05%), respectively.",Population PK/PD analysis of metformin using the signal transduction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380769/),,0.547,18118,DB00331,Metformin
,30517974,m/z,"Ion transitions studied using multiple reaction monitoring mode were m/z 130.1 [M + H]+ /60.1 for metformin and m/z 467.1 [M + CH3 COO]- /329.1 for dapagliflozin in the positive and negative modes, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),,130.1,18350,DB00331,Metformin
,30517974,m/z,"Ion transitions studied using multiple reaction monitoring mode were m/z 130.1 [M + H]+ /60.1 for metformin and m/z 467.1 [M + CH3 COO]- /329.1 for dapagliflozin in the positive and negative modes, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),,467.1,18351,DB00331,Metformin
,30517974,limit of detection,"The limit of detection and limit of quantitation for the analytes were 0.39 and 1.0 ng/mL for metformin and 0.03 and 0.1 ng/mL for dapagliflozin, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),[ng] / [ml],0.39,18352,DB00331,Metformin
,30517974,limit of detection,"The limit of detection and limit of quantitation for the analytes were 0.39 and 1.0 ng/mL for metformin and 0.03 and 0.1 ng/mL for dapagliflozin, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),[ng] / [ml],0.03,18353,DB00331,Metformin
,30517974,limit of quantitation,"The limit of detection and limit of quantitation for the analytes were 0.39 and 1.0 ng/mL for metformin and 0.03 and 0.1 ng/mL for dapagliflozin, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),[ng] / [ml],1.0,18354,DB00331,Metformin
,30517974,limit of quantitation,"The limit of detection and limit of quantitation for the analytes were 0.39 and 1.0 ng/mL for metformin and 0.03 and 0.1 ng/mL for dapagliflozin, respectively.",Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30517974/),[ng] / [ml],0.1,18355,DB00331,Metformin
,24755124,peak plasma concentrations,"After food intake, peak plasma concentrations of linagliptin were slightly lowered (from 4.99 to 4.56 nmol L⁻¹), but the 90% confidence interval (CI) of the geometric mean test/reference ratio was still located within the generally applied bioequivalence acceptance limits of 80 - 125%.",Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),l⁻¹·nM,4.99,19023,DB00331,Metformin
,24755124,peak plasma concentrations,"After food intake, peak plasma concentrations of linagliptin were slightly lowered (from 4.99 to 4.56 nmol L⁻¹), but the 90% confidence interval (CI) of the geometric mean test/reference ratio was still located within the generally applied bioequivalence acceptance limits of 80 - 125%.",Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),l⁻¹·nM,4.56,19024,DB00331,Metformin
,24755124,tmax,Administration with food reduced the rate of absorption of metformin indicated by a prolongation in median tmax (from 2 to 4 hours) and a decrease in Cmax by ~ 18%.,Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),h,2,19025,DB00331,Metformin
,24755124,tmax,Administration with food reduced the rate of absorption of metformin indicated by a prolongation in median tmax (from 2 to 4 hours) and a decrease in Cmax by ~ 18%.,Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),h,4,19026,DB00331,Metformin
>,32706921,f2,"The dissolution profiles of the generic formulation expressed obvious extended-release properties, similar to those of the branded formulation (f2 > 60.0%).",In Vitro Dissolution and In Vivo Bioequivalence Evaluation of Two Metformin Extended-Release Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706921/),%,60.0,19149,DB00331,Metformin
,29175695,extraction recovery,The extraction recovery was about 97% for L-DOX and about 65% for NL-DOX.,Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175695/),%,97,20002,DB00331,Metformin
,29175695,extraction recovery,The extraction recovery was about 97% for L-DOX and about 65% for NL-DOX.,Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175695/),%,65,20003,DB00331,Metformin
,17515289,maximum concentration (C(max)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[μg] / [ml],1.73,20629,DB00331,Metformin
,17515289,time to reach maximum concentration (T(max)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[μg] / [ml],1.86,20630,DB00331,Metformin
,17515289,time to reach maximum concentration (T(max)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[h·μg] / [ml],11.53,20631,DB00331,Metformin
,17515289,area under the curve (AUC(0 --> t),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[μg] / [ml],1.86,20632,DB00331,Metformin
,17515289,area under the curve (AUC(0 --> t),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[h·μg] / [ml],11.53,20633,DB00331,Metformin
,17515289,AUC(0 --> infinity)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[μg] / [ml],1.86,20634,DB00331,Metformin
,17515289,AUC(0 --> infinity)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[h·μg] / [ml],11.53,20635,DB00331,Metformin
,17515289,elimination half-life (t(1/2)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),[h·μg] / [ml],11.6,20636,DB00331,Metformin
,17515289,elimination half-life (t(1/2)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),h,3.1,20637,DB00331,Metformin
,17515289,elimination half-life (t(1/2)),"Mean +/- SD maximum concentration (C(max)), time to reach maximum concentration (T(max)), area under the curve (AUC(0 --> t) and AUC(0 --> infinity)), and elimination half-life (t(1/2)) were 1.73 +/- 0.54 and 1.86 +/- 0.67 microg/ml, 2.6 +/- 1.2 and 2.0 +/- 1.0 h, 10.72 +/- 3.93 and 10.82 +/- 3.72 microg x h/ml, 11.53 - 4.14 and 11.6 +/- 3.84 microg x h/ml, and 3.1 +/- 0.7 and 3.1 +/- 0.9 h for the test and reference formulation, respectively.",Bioequivalence study of two metformin formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515289/),h,3.1,20638,DB00331,Metformin
,34371742,loading capacity (LC),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,14.9,21067,DB00331,Metformin
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,15.2,21068,DB00331,Metformin
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),,30.3,21069,DB00331,Metformin
,26597253,unbound concentrations,"Famotidine unbound concentrations in plasma reached 1 µM, thus exceeding the in vitro concentrations that inhibit MATE1 [concentration of drug producing 50 % inhibition (IC50) 0.25 µM].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),μM,1,21669,DB00331,Metformin
,26597253,concentration of drug producing 50 % inhibition (IC50),"Famotidine unbound concentrations in plasma reached 1 µM, thus exceeding the in vitro concentrations that inhibit MATE1 [concentration of drug producing 50 % inhibition (IC50) 0.25 µM].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),μM,0.25,21670,DB00331,Metformin
>,26597253,"maximum unbound plasma drug concentration (C max,u)/IC50","Based on current regulatory guidance, these concentrations are expected to inhibit MATE1 clinically [i.e. maximum unbound plasma drug concentration (C max,u)/IC50 >0.1].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),,0.1,21671,DB00331,Metformin
,12436333,milk-to-plasma ratio,The mean milk-to-plasma ratio for metformin was 0.35 (95%CI 0.2-0.5).,Transfer of metformin into human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12436333/),,0.35,23671,DB00331,Metformin
,3710634,recovery,"The recovery of metformin in urine was 37%, 33%, 25%, 28% and 29% of the dose after A, B, C, D and E, respectively.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),%,37,23765,DB00331,Metformin
,3710634,recovery,"The recovery of metformin in urine was 37%, 33%, 25%, 28% and 29% of the dose after A, B, C, D and E, respectively.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),%,33,23766,DB00331,Metformin
,3710634,recovery,"The recovery of metformin in urine was 37%, 33%, 25%, 28% and 29% of the dose after A, B, C, D and E, respectively.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),%,25,23767,DB00331,Metformin
,3710634,recovery,"The recovery of metformin in urine was 37%, 33%, 25%, 28% and 29% of the dose after A, B, C, D and E, respectively.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),%,28,23768,DB00331,Metformin
,3710634,recovery,"The recovery of metformin in urine was 37%, 33%, 25%, 28% and 29% of the dose after A, B, C, D and E, respectively.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),%,29,23769,DB00331,Metformin
,3710634,renal clearance,"The renal clearance of metformin was similar after all the products, averaging 518 +/- 16 (SE) ml/min.","Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),[ml] / [min],518,23770,DB00331,Metformin
,3710634,terminal elimination half-life,The terminal elimination half-life on the basis of urinary excretion rate data averaged 12.6 +/- 0.6 h with no significant difference between the products.,"Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710634/),h,12.6,23771,DB00331,Metformin
,33051249,F:M ratio,The model-predicted F:M ratio (approx. 0.88) is consistent with reported in vivo values [mean (95% confidence interval): 1.10 (0.69-1.51)].,Development of a Pharmacokinetic Model of Transplacental Transfer of Metformin to Predict In Vivo Fetal Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051249/),,0.,24847,DB00331,Metformin
,8904626,Bioavailability,Bioavailability of a 500 mg tablet is 14% greater than that of an 850 mg tablet.,"Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904626/),%,14,24848,DB00331,Metformin
,8904626,bioavailability,"Compared with the fasting state, bioavailability is 24% lower, and the peak concentration delayed about 37 min when an 850 mg tablet is administered with food.","Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904626/),%,24,24849,DB00331,Metformin
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],504,25697,DB00331,Metformin
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],557,25698,DB00331,Metformin
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],240,25699,DB00331,Metformin
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],269,25700,DB00331,Metformin
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],342,25701,DB00331,Metformin
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],76,25702,DB00331,Metformin
,16937336,absolute oral bioavailability (F),"After oral administration (100 mg/kg), approximately 4.39% of oral dose was not absorbed and extent of absolute oral bioavailability (F) value was approximately 29.9%.",Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16937336/),%,29.9,25707,DB00331,Metformin
,16937336,first,"The gastrointestinal first-pass effect of metformin was approximately 53.8% of oral dose in rats (the gastric and intestinal first-pass effects were approximately 23.1 and 30.7%, respectively), and the hepatic first-pass effect was approximately 27.1% after absorption into the portal vein.",Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16937336/),,23,25708,DB00331,Metformin
,24374443,flow rate,Potassium dihydrogen phosphate containing 0.25mL/L triethylamine at pH 3.5 (adjusted with 1:1 phosphoric acid) and acetonitrile (465: 535v/v) was delivered with injection volume of 100μL at flow rate of 1 mL/min at 25°C temperature.,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ml] / [min],1,26334,DB00331,Metformin
,24374443,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax was 131.856±8.050ng/ml for Glibenclamide (Mean ± SEM) and 511.106±12.675 ng/ml for Metformin HCl (Mean ±SEM).,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ng] / [ml],131.856,26335,DB00331,Metformin
,24374443,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax was 131.856±8.050ng/ml for Glibenclamide (Mean ± SEM) and 511.106±12.675 ng/ml for Metformin HCl (Mean ±SEM).,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ng] / [ml],511.106,26336,DB00331,Metformin
,25940675,terminal half-lives,"Plasma PF-05231023 levels peaked immediately post-IV dosing, with mean terminal half-lives of 6.5-7.7 h and 66.5- 96.6 h for intact C- and N-termini, respectively.","Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940675/),h,6.5-7.7,27564,DB00331,Metformin
,25940675,terminal half-lives,"Plasma PF-05231023 levels peaked immediately post-IV dosing, with mean terminal half-lives of 6.5-7.7 h and 66.5- 96.6 h for intact C- and N-termini, respectively.","Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940675/),h,66.5- 96.6,27565,DB00331,Metformin
,26285584,bioavailability,"The bioavailability of 1,000 mg Met DR b.i.d. was ∼50% that of Met IR and Met XR (study 1).","The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26285584/),%,∼50,29159,DB00331,Metformin
,25223504,area under the glucose concentration-time curve,"The addition of St John's wort decreased the area under the glucose concentration-time curve [702 (95% confidence interval, 643-761) vs. 629 min*mmol/L (95% confidence interval, 568-690), P = 0.003], and this effect was caused by a statistically significant increase in the acute insulin response.",Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223504/),[mM·min] / [l],702,31100,DB00331,Metformin
,25223504,area under the glucose concentration-time curve,"The addition of St John's wort decreased the area under the glucose concentration-time curve [702 (95% confidence interval, 643-761) vs. 629 min*mmol/L (95% confidence interval, 568-690), P = 0.003], and this effect was caused by a statistically significant increase in the acute insulin response.",Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223504/),[mM·min] / [l],629,31101,DB00331,Metformin
,30538075,AUC,"Moreover, telmisartan co-administration significantly increased the plasma concentrations of both glucose and insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min vs 60.20 ± 24.20 μIU/ml·min, P = 0.037), though the AUC of glucose and insulin after OGTT showed no significant difference.",The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30538075/),mm,6.77,32303,DB00331,Metformin
,30538075,AUC,"Moreover, telmisartan co-administration significantly increased the plasma concentrations of both glucose and insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min vs 60.20 ± 24.20 μIU/ml·min, P = 0.037), though the AUC of glucose and insulin after OGTT showed no significant difference.",The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30538075/),[μiu] / [min·ml],72.91,32304,DB00331,Metformin
,12909816,elimination half-life,"However, because the elimination half-life of metformin was much longer in erythrocytes (23.4 +/- 1.9 h vs. 2.7 +/- 1.2 h), there was no difference in area under the curve between plasma and erythrocytes.",Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12909816/),h,23.4,35857,DB00331,Metformin
,12909816,elimination half-life,"However, because the elimination half-life of metformin was much longer in erythrocytes (23.4 +/- 1.9 h vs. 2.7 +/- 1.2 h), there was no difference in area under the curve between plasma and erythrocytes.",Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12909816/),h,2.7,35858,DB00331,Metformin
,12909816,distribution volume (plasma),The distribution volume (plasma) was calculated to be 146 +/- 11 l.,Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12909816/),l,146,35859,DB00331,Metformin
,18237462,intrinsic clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [mg·min],0.0350,40317,DB00331,Metformin
,18237462,intrinsic clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [mg·min],0.0309,40318,DB00331,Metformin
,18237462,intrinsic clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [mg·min],0.0253,40319,DB00331,Metformin
,18237462,intrinsic clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [mg·min],0.0316,40320,DB00331,Metformin
,18237462,total area under the plasma concentration-time curve from time zero to time infinity (AUC,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],4110,40321,DB00331,Metformin
,18237462,total area under the plasma concentration-time curve from time zero to time infinity (AUC,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],4290,40322,DB00331,Metformin
,18237462,total area under the plasma concentration-time curve from time zero to time infinity (AUC,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],5540,40323,DB00331,Metformin
,18237462,total area under the plasma concentration-time curve from time zero to time infinity (AUC,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],4430,40324,DB00331,Metformin
,18237462,time-averaged non-renal clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [kg·min],8.12,40325,DB00331,Metformin
,18237462,time-averaged non-renal clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [kg·min],7.95,40326,DB00331,Metformin
,18237462,time-averaged non-renal clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [kg·min],5.94,40327,DB00331,Metformin
,18237462,time-averaged non-renal clearance,"The following pharmacokinetic parameters of metformin following i.v. administration were restored from levels in PCM rats to levels in control rats in PCMC rats: intrinsic clearance (0.0350, 0.0309, 0.0253 and 0.0316 mL min(-1) mg(-1) protein for control, CC, PCM, and PCMC rats, respectively), total area under the plasma concentration-time curve from time zero to time infinity (AUC; 4110, 4290, 5540 and 4430 microg min mL(-1), respectively), and time-averaged non-renal clearance (8.12, 7.95, 5.94 and 8.17 mL min(-1) kg(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[ml] / [kg·min],8.17,40328,DB00331,Metformin
,18237462,AUC,"AUC values following oral administration were comparable between control and PCMC rats (1520, 1480, 2290 and 1680 microg min mL(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],1520,40329,DB00331,Metformin
,18237462,AUC,"AUC values following oral administration were comparable between control and PCMC rats (1520, 1480, 2290 and 1680 microg min mL(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],1480,40330,DB00331,Metformin
,18237462,AUC,"AUC values following oral administration were comparable between control and PCMC rats (1520, 1480, 2290 and 1680 microg min mL(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],2290,40331,DB00331,Metformin
,18237462,AUC,"AUC values following oral administration were comparable between control and PCMC rats (1520, 1480, 2290 and 1680 microg min mL(-1), respectively).",Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237462/),[min·μg] / [ml],1680,40332,DB00331,Metformin
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],910,40878,DB00331,Metformin
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],472,40879,DB00331,Metformin
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],950,40880,DB00331,Metformin
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],433,40881,DB00331,Metformin
,29457876,peak concentration,"No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0-24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mg] / [l],2.1,41099,DB00331,Metformin
,29457876,peak concentration,"No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0-24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mg] / [l],2.0,41100,DB00331,Metformin
,29457876,time to peak concentration,"No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0-24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),h,2.5,41101,DB00331,Metformin
,29457876,area under the curve (AUC)0-24,"No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0-24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mg] / [h·l],16.9,41102,DB00331,Metformin
,29457876,area under the curve (AUC)0-24,"No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0-24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mg] / [h·l],13.9,41103,DB00331,Metformin
,29457876,peak concentration,"Lactate concentration peaked at 3.5 hours, with mean peak concentration of 2.4 mmol/L in both cohorts (95% CI 2.0-2.8 and 1.8-3.0 mmol/L, respectively), and similar incremental AUC0-24 in each cohort: tolerant cohort 6.98 (95% CI 3.03-10.93) and intolerant cohort 4.47 (95% CI -3.12-12.06) mmol/L*h (P = .55).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mM] / [l],2.4,41104,DB00331,Metformin
,29457876,AUC0-24,"Lactate concentration peaked at 3.5 hours, with mean peak concentration of 2.4 mmol/L in both cohorts (95% CI 2.0-2.8 and 1.8-3.0 mmol/L, respectively), and similar incremental AUC0-24 in each cohort: tolerant cohort 6.98 (95% CI 3.03-10.93) and intolerant cohort 4.47 (95% CI -3.12-12.06) mmol/L*h (P = .55).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mM] / [h·l],6.98,41105,DB00331,Metformin
,29457876,AUC0-24,"Lactate concentration peaked at 3.5 hours, with mean peak concentration of 2.4 mmol/L in both cohorts (95% CI 2.0-2.8 and 1.8-3.0 mmol/L, respectively), and similar incremental AUC0-24 in each cohort: tolerant cohort 6.98 (95% CI 3.03-10.93) and intolerant cohort 4.47 (95% CI -3.12-12.06) mmol/L*h (P = .55).",Pharmacokinetics of metformin in patients with gastrointestinal intolerance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457876/),[mM] / [h·l],4.47,41106,DB00331,Metformin
,28474741,AUC0-2,"The geometric mean AUC0-2 for insulin, glucose and lactate during treatments A and B were 84 h.",Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28474741/),h,84,42723,DB00331,Metformin
,32763846,flow rate,"The mobile phase consisted of methanol and 5 mM ammonium trifluoroacetate in water, pH 5 (50:50, v/v) at a flow rate of 0.8 mL/min.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ml] / [min],0.8,44256,DB00331,Metformin
,32763846,m/z,"Also, for metformin transitions were monitored at m/z 130.0 → m/z 71.1.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,71.1,44257,DB00331,Metformin
,32763846,Linearity,Linearity was in the range of 24.95-2806.55 ng/mL for canagliflozin and 24.99-3400.72 ng/mL for metformin.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ng] / [ml],24.95-2806.55,44258,DB00331,Metformin
,32763846,Linearity,Linearity was in the range of 24.95-2806.55 ng/mL for canagliflozin and 24.99-3400.72 ng/mL for metformin.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ng] / [ml],24.99-3400.72,44259,DB00331,Metformin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,77.240,44260,DB00331,Metformin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,84.663,44261,DB00331,Metformin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,66.747,44262,DB00331,Metformin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,67.449,44263,DB00331,Metformin
,32763846,run time,This rapid method with the run time of 2.80 min allows the analysis of more than 400 plasma samples per day.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),min,2.80,44264,DB00331,Metformin
,6832864,peak serum level,"In the single-dose trial the mean peak serum level of 1.00 micrograms/ml from RRM and 0.61 micrograms/ml from SRM were reached at 3 h, and at 3 and 4 h, respectively, after ingestion of the drugs.",The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),[μg] / [ml],1.00,44716,DB00331,Metformin
,6832864,peak serum level,"In the single-dose trial the mean peak serum level of 1.00 micrograms/ml from RRM and 0.61 micrograms/ml from SRM were reached at 3 h, and at 3 and 4 h, respectively, after ingestion of the drugs.",The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),[μg] / [ml],0.61,44717,DB00331,Metformin
,6832864,AUC0-8h,"Serum metformin levels from RRM were consistently higher up to 8 h, and the AUC0-8h value for RRM was from 4.25 and 2.49 for SRM (p less than 0.001).",The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),,4.25,44718,DB00331,Metformin
,6832864,AUC0-8h,"Serum metformin levels from RRM were consistently higher up to 8 h, and the AUC0-8h value for RRM was from 4.25 and 2.49 for SRM (p less than 0.001).",The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),,2.49,44719,DB00331,Metformin
,6832864,elimination half-life,The elimination half-life was 2.0 h for RRM and 2.6 h for SRM.,The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),h,2.0,44720,DB00331,Metformin
,6832864,elimination half-life,The elimination half-life was 2.0 h for RRM and 2.6 h for SRM.,The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),h,2.6,44721,DB00331,Metformin
,6832864,AUC0-8h,On the 5th day the AUC0-8h values obtained after RRM and SRM were comparable (6.88 vs 6.59; N.S.).,The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),,6.88,44722,DB00331,Metformin
,6832864,AUC0-8h,On the 5th day the AUC0-8h values obtained after RRM and SRM were comparable (6.88 vs 6.59; N.S.).,The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832864/),,6.59,44723,DB00331,Metformin
,27508356,extraction recoveries,"The extraction recoveries obtained from spiked plasma samples were highly consistent for MET (75.12-77.84%), SAXA (85.90-87.84%) and 5-OH SAXA (80.32-82.69%) across quality controls.","LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27508356/),%,75.12-77.84,45676,DB00331,Metformin
,27508356,extraction recoveries,"The extraction recoveries obtained from spiked plasma samples were highly consistent for MET (75.12-77.84%), SAXA (85.90-87.84%) and 5-OH SAXA (80.32-82.69%) across quality controls.","LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27508356/),%,85.90-87.84,45677,DB00331,Metformin
,27508356,extraction recoveries,"The extraction recoveries obtained from spiked plasma samples were highly consistent for MET (75.12-77.84%), SAXA (85.90-87.84%) and 5-OH SAXA (80.32-82.69%) across quality controls.","LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27508356/),%,80.32-82.69,45678,DB00331,Metformin
,22105592,C(max),The mean C(max) of 1.9 ± 0.6 mg/L was attained at 4.1 ± 1.9 hours.,Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105592/),[mg] / [l],1.9,45877,DB00331,Metformin
,22105592,ClCr,ClCr showed no significant difference (P > 0.05) before (92.8 ± 11.3 mL/min) and after 48 hours (90.5 ± 10.5 mL/min) of exposure to CM.,Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105592/),[ml] / [min],92.8,45878,DB00331,Metformin
,22105592,ClCr,ClCr showed no significant difference (P > 0.05) before (92.8 ± 11.3 mL/min) and after 48 hours (90.5 ± 10.5 mL/min) of exposure to CM.,Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105592/),[ml] / [min],90.5,45879,DB00331,Metformin
,24588963,EC50,"From a library of synthesized compounds, 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methyl pyridin-2-yl)-benzamide (19e) was identified as a potent glucokinase activator with assays demonstrating an EC50 of 315nM and the induction of a 2.23 fold increase in glucose uptake.",Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588963/),nM,315,47626,DB00331,Metformin
,20871764,C(max 1),"The C(max 1), 2.62 ± 0.32 μg/ml, and C(max 2,) 2.96 ± 0.65 μg/ml, occurred after 0.75 and 3 h post-dose, respectively.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[μg] / [ml],2.62,48016,DB00331,Metformin
,20871764,"C(max 2,)","The C(max 1), 2.62 ± 0.32 μg/ml, and C(max 2,) 2.96 ± 0.65 μg/ml, occurred after 0.75 and 3 h post-dose, respectively.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[μg] / [ml],2.96,48017,DB00331,Metformin
,20871764,mean residence time (MRT),"The mean residence time (MRT), AUC(0-4 h) and volume of distribution (Vd/F) were 4.20 ± 0.30 h, 8.53 ± 1.89 μg.h/ml and 14.24 ± 5.42 L/kg, respectively.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),h,4.20,48018,DB00331,Metformin
,20871764,AUC(0-4 h),"The mean residence time (MRT), AUC(0-4 h) and volume of distribution (Vd/F) were 4.20 ± 0.30 h, 8.53 ± 1.89 μg.h/ml and 14.24 ± 5.42 L/kg, respectively.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[h·μg] / [ml],8.53,48019,DB00331,Metformin
,20871764,volume of distribution (Vd/F),"The mean residence time (MRT), AUC(0-4 h) and volume of distribution (Vd/F) were 4.20 ± 0.30 h, 8.53 ± 1.89 μg.h/ml and 14.24 ± 5.42 L/kg, respectively.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[l] / [kg],14.24,48020,DB00331,Metformin
,20871764,"C(max 1,)","Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C(max) (C(max 1,) 3.96 ± 0.55 μg/ml and C(max 2,) 5.21 ± 0.59 μg/ml), AUC(0-4 h) (12.28 ± 0.73 μg.h/ml) and Vd/F (18.29 ± 1.19 L/kg), but lower MRT (3.19 ± 0.36 h) than the values obtained after metformin dosing alone.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[μg] / [ml],3.96,48021,DB00331,Metformin
,20871764,"C(max 2,)","Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C(max) (C(max 1,) 3.96 ± 0.55 μg/ml and C(max 2,) 5.21 ± 0.59 μg/ml), AUC(0-4 h) (12.28 ± 0.73 μg.h/ml) and Vd/F (18.29 ± 1.19 L/kg), but lower MRT (3.19 ± 0.36 h) than the values obtained after metformin dosing alone.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[μg] / [ml],5.21,48022,DB00331,Metformin
,20871764,AUC(0-4 h),"Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C(max) (C(max 1,) 3.96 ± 0.55 μg/ml and C(max 2,) 5.21 ± 0.59 μg/ml), AUC(0-4 h) (12.28 ± 0.73 μg.h/ml) and Vd/F (18.29 ± 1.19 L/kg), but lower MRT (3.19 ± 0.36 h) than the values obtained after metformin dosing alone.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[h·μg] / [ml],12.28,48023,DB00331,Metformin
,20871764,Vd/F,"Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C(max) (C(max 1,) 3.96 ± 0.55 μg/ml and C(max 2,) 5.21 ± 0.59 μg/ml), AUC(0-4 h) (12.28 ± 0.73 μg.h/ml) and Vd/F (18.29 ± 1.19 L/kg), but lower MRT (3.19 ± 0.36 h) than the values obtained after metformin dosing alone.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[l] / [kg],18.29,48024,DB00331,Metformin
,20871764,MRT,"Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C(max) (C(max 1,) 3.96 ± 0.55 μg/ml and C(max 2,) 5.21 ± 0.59 μg/ml), AUC(0-4 h) (12.28 ± 0.73 μg.h/ml) and Vd/F (18.29 ± 1.19 L/kg), but lower MRT (3.19 ± 0.36 h) than the values obtained after metformin dosing alone.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),h,3.19,48025,DB00331,Metformin
,20871764,AUC(0-t),"However, AUC(0-t) (17.74 ± 5.58 μg.h/ml) and clearance (3.76 ± 0.80 L/h/kg) remained unchanged.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[h·μg] / [ml],17.74,48026,DB00331,Metformin
,20871764,clearance,"However, AUC(0-t) (17.74 ± 5.58 μg.h/ml) and clearance (3.76 ± 0.80 L/h/kg) remained unchanged.",Effect of centchroman coadministration on the pharmacokinetics of metformin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871764/),[l] / [h·kg],3.76,48027,DB00331,Metformin
,32789583,total amount,"The total amount of metformin removed by 6 h of hemodialysis was 888 mg, approximately equivalent to one therapeutic dose.",A Pharmacokinetic Analysis of Hemodialysis for Metformin-Associated Lactic Acidosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32789583/),,88,48173,DB00331,Metformin
,23873119,CL(renal),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],28.1,48484,DB00331,Metformin
,23873119,CL(renal),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],34.5,48485,DB00331,Metformin
,23873119,CL(renal),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],44.8,48486,DB00331,Metformin
,23873119,CL(sec),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],21.4,48487,DB00331,Metformin
,23873119,CL(sec),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],27.8,48488,DB00331,Metformin
,23873119,CL(sec),"However, both CL(renal) and CL(sec) were increased for the volunteers with minor alleles in c.808 (G>T) who were also homozygous for the reference variant g.-66T>C: CL(renal): GG, GT, and TT: 28.1, 34.5, and 44.8 l/h (P = 0.004), respectively and CL(sec): GG, GT, and TT: 21.4, 27.8, and 37.6 l/h (P = 0.005), respectively.",A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873119/),[l] / [h],37.6,48489,DB00331,Metformin
,16106359,LC retention times,"The LC retention times for isoniazid and ethambutol were 2.46 and 2.27 min, respectively.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16106359/),min,2.46,49783,DB00331,Metformin
,16106359,LC retention times,"The LC retention times for isoniazid and ethambutol were 2.46 and 2.27 min, respectively.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16106359/),min,2.27,49784,DB00331,Metformin
,31362250,extraction recovery,The extraction recovery ranged from 79 to 88% for all the analytes.,Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31362250/),%,79 to 88,50267,DB00331,Metformin
,18471347,t(max),"Administration of the fixed-dose combination tablet following a high-fat meal had no effect on vildagliptin AUC(0-infinity) (ratio of geometric mean for fed:fasted state, 1.10 [90% CI 1.03, 1.18]), C(max) (ratio of means 0.98 [90% CI 0.85, 1.13]) or median t(max) (2.5 h in fed and fasted states).",Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471347/),h,2.5,50390,DB00331,Metformin
,18471347,t(max),"The rate of absorption of metformin was decreased when given with food, as reflected by the prolonged t(max) (2-4 h) and reduction in C(max) (by 26%), but the extent of absorption was not changed.",Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471347/),h,2-4,50391,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,357.2,51277,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,134.2,51278,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,373.0,51279,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,150.1,51280,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,130.2,51281,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,71.0,51282,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,361.1,51283,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,134.2,51284,DB00331,Metformin
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,136.1,51285,DB00331,Metformin
,23732843,total chromatographic run time,The total chromatographic run time was 4.0min.,"Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),min,4.0,51286,DB00331,Metformin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,1,52327,DB00331,Metformin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,2,52328,DB00331,Metformin
,32337660,terminal phase half-life,The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,11 to 18,52329,DB00331,Metformin
,32337660,absolute bioavailability,Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),%,100,52330,DB00331,Metformin
,28932995,peak-reaching time (t max),rE-4 was absorbed quickly with a median peak-reaching time (t max) of 0.8-1.5 h and eliminated rapidly with a median terminal half-life (t 1/2z) of 1.6-1.9 h.,Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932995/),h,0.8-1.5,54116,DB00331,Metformin
,28932995,terminal half-life (t 1/2z),rE-4 was absorbed quickly with a median peak-reaching time (t max) of 0.8-1.5 h and eliminated rapidly with a median terminal half-life (t 1/2z) of 1.6-1.9 h.,Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932995/),h,1.6-1.9,54117,DB00331,Metformin
,15966755,time to maximum plasma concentration,Absorption of metformin XR was slower than that of metformin IR (time to maximum plasma concentration = 7 versus 3 hours).,Steady-state pharmacokinetics of a novel extended-release metformin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966755/),h,7,54994,DB00331,Metformin
,15966755,time to maximum plasma concentration,Absorption of metformin XR was slower than that of metformin IR (time to maximum plasma concentration = 7 versus 3 hours).,Steady-state pharmacokinetics of a novel extended-release metformin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966755/),h,3,54995,DB00331,Metformin
,15966755,accumulation ratio,"The mean accumulation ratio of metformin XR was 1.0, indicating no accumulation with multiple-dose administration.",Steady-state pharmacokinetics of a novel extended-release metformin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966755/),,1.0,54996,DB00331,Metformin
,23018469,elimination half-life,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,3.75,55343,DB00331,Metformin
,23018469,elimination half-life,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,4.00,55344,DB00331,Metformin
,23018469,time to maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,2.00,55345,DB00331,Metformin
,23018469,time to maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,3.00,55346,DB00331,Metformin
,23018469,maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],1.42,55347,DB00331,Metformin
,23018469,maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],1.21,55348,DB00331,Metformin
,23018469,concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],0.53,55349,DB00331,Metformin
,23018469,concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],0.56,55350,DB00331,Metformin
,23018469,area under the plasma concentration-time curve from time zero to 12 h,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[h·μg] / [ml],6.42,55351,DB00331,Metformin
,23018469,area under the plasma concentration-time curve from time zero to 12 h,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[h·μg] / [ml],6.73,55352,DB00331,Metformin
,23018469,apparent total oral clearance,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[l] / [h],105.39,55353,DB00331,Metformin
,23018469,apparent total oral clearance,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[l] / [h],98.38,55354,DB00331,Metformin
,23018469,apparent volume of distribution,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),l,550.51,55355,DB00331,Metformin
,23018469,apparent volume of distribution,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),l,490.98,55356,DB00331,Metformin
,29342199,area under the concentration-time curve from dosing to 12 hours post-dose (AUC0-12h),"The mean values for the area under the concentration-time curve from dosing to 12 hours post-dose (AUC0-12h) were 3160.4 and 8808.2 h·μg/L for the low- and high-dose groups, respectively.","A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342199/),[h·μg] / [l],3160.4,56258,DB00331,Metformin
,29342199,area under the concentration-time curve from dosing to 12 hours post-dose (AUC0-12h),"The mean values for the area under the concentration-time curve from dosing to 12 hours post-dose (AUC0-12h) were 3160.4 and 8808.2 h·μg/L for the low- and high-dose groups, respectively.","A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342199/),[h·μg] / [l],8808.2,56259,DB00331,Metformin
,22407892,F,Oral bioavailability was not affected (F = 64 ± 4 versus 59 ± 11; knockout versus wild type).,Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),,64,59837,DB00331,Metformin
,22407892,F,Oral bioavailability was not affected (F = 64 ± 4 versus 59 ± 11; knockout versus wild type).,Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),,59,59838,DB00331,Metformin
,22407892,ED50,"Oral glucose area under the curve (AUC) lowering by metformin was not impaired in Oct1/Oct2-knockout mice at the five dose levels tested (ED50 = 151 versus 110 mg/kg; glucose lowering at highest dose = 42 ± 1 versus 39 ± 4%; knockout versus wild type); however, higher systemic metformin exposures were necessary in knockout mice to elicit the same effect (half-maximal efficacious AUC = 70 versus 26 μg x h/ml).",Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),[mg] / [kg],151,59839,DB00331,Metformin
,22407892,ED50,"Oral glucose area under the curve (AUC) lowering by metformin was not impaired in Oct1/Oct2-knockout mice at the five dose levels tested (ED50 = 151 versus 110 mg/kg; glucose lowering at highest dose = 42 ± 1 versus 39 ± 4%; knockout versus wild type); however, higher systemic metformin exposures were necessary in knockout mice to elicit the same effect (half-maximal efficacious AUC = 70 versus 26 μg x h/ml).",Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),[mg] / [kg],110,59840,DB00331,Metformin
,22407892,half-maximal efficacious AUC,"Oral glucose area under the curve (AUC) lowering by metformin was not impaired in Oct1/Oct2-knockout mice at the five dose levels tested (ED50 = 151 versus 110 mg/kg; glucose lowering at highest dose = 42 ± 1 versus 39 ± 4%; knockout versus wild type); however, higher systemic metformin exposures were necessary in knockout mice to elicit the same effect (half-maximal efficacious AUC = 70 versus 26 μg x h/ml).",Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),[h·μg] / [ml],70,59841,DB00331,Metformin
,22407892,half-maximal efficacious AUC,"Oral glucose area under the curve (AUC) lowering by metformin was not impaired in Oct1/Oct2-knockout mice at the five dose levels tested (ED50 = 151 versus 110 mg/kg; glucose lowering at highest dose = 42 ± 1 versus 39 ± 4%; knockout versus wild type); however, higher systemic metformin exposures were necessary in knockout mice to elicit the same effect (half-maximal efficacious AUC = 70 versus 26 μg x h/ml).",Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407892/),[h·μg] / [ml],26,59842,DB00331,Metformin
,20118196,renal clearance,"Metformin renal clearance increased significantly in mid (723 +/- 243 ml/min, P < 0.01) and late pregnancy (625 +/- 130 ml/min, P < 0.01) compared with postpartum (477 +/- 132 ml/min).",Pharmacokinetics of metformin during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],723,60933,DB00331,Metformin
,20118196,renal clearance,"Metformin renal clearance increased significantly in mid (723 +/- 243 ml/min, P < 0.01) and late pregnancy (625 +/- 130 ml/min, P < 0.01) compared with postpartum (477 +/- 132 ml/min).",Pharmacokinetics of metformin during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],625,60934,DB00331,Metformin
,20118196,renal clearance,"Metformin renal clearance increased significantly in mid (723 +/- 243 ml/min, P < 0.01) and late pregnancy (625 +/- 130 ml/min, P < 0.01) compared with postpartum (477 +/- 132 ml/min).",Pharmacokinetics of metformin during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],477,60935,DB00331,Metformin
,20118196,net secretion clearance,"These changes reflected significant increases in creatinine clearance (240 +/- 70 ml/min, P < 0.01 and 207 +/- 56 ml/min, P < 0.05 versus 165 +/- 44 ml/min) and in metformin net secretion clearance (480 +/- 190 ml/min, P < 0.01 and 419 +/- 78 ml/min, P < 0.01 versus 313 +/- 98 ml/min) in mid and late pregnancy versus postpartum, respectively.",Pharmacokinetics of metformin during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],480,60936,DB00331,Metformin
,20118196,net secretion clearance,"These changes reflected significant increases in creatinine clearance (240 +/- 70 ml/min, P < 0.01 and 207 +/- 56 ml/min, P < 0.05 versus 165 +/- 44 ml/min) and in metformin net secretion clearance (480 +/- 190 ml/min, P < 0.01 and 419 +/- 78 ml/min, P < 0.01 versus 313 +/- 98 ml/min) in mid and late pregnancy versus postpartum, respectively.",Pharmacokinetics of metformin during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],419,60937,DB00331,Metformin
,20118196,net secretion clearance,"These changes reflected significant increases in creatinine clearance (240 +/- 70 ml/min, P < 0.01 and 207 +/- 56 ml/min, P < 0.05 versus 165 +/- 44 ml/min) and in metformin net secretion clearance (480 +/- 190 ml/min, P < 0.01 and 419 +/- 78 ml/min, P < 0.01 versus 313 +/- 98 ml/min) in mid and late pregnancy versus postpartum, respectively.",Pharmacokinetics of metformin during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20118196/),[ml] / [min],313,60938,DB00331,Metformin
>,26062557,blood-to-plasma partition ratio (B/P),Blood cells are considered an important distributional compartment for metformin based on the high blood-to-plasma partition ratio (B/P) in humans (>10 at Cmin).,Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),,10,62685,DB00331,Metformin
,26062557,intrinsic equilibrium B/P,"The results showed that metformin's intrinsic equilibrium B/P was ∼0.8-1.4 in blood, which is <10% of the reported clinical value.",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),,∼0.8-1.4,62686,DB00331,Metformin
,26062557,half-life,Kinetics of metformin partitioning into human blood cells and repartitioning back into plasma were slow (repartitioning half-life ∼32-39 hours).,Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),h,39,62687,DB00331,Metformin
,26062557,plasma renal extraction ratio,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),%,∼90,62688,DB00331,Metformin
,26062557,plasma renal extraction ratio,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),%,100,62689,DB00331,Metformin
,26062557,clinical,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),h,6,62690,DB00331,Metformin
,26062557,terminal half-life,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),h,6,62691,DB00331,Metformin
,26062557,half-life,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),h,18,62692,DB00331,Metformin
,26062557,half-life,"These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours).",Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),h,23,62693,DB00331,Metformin
,26062557,rate constant,The rate constant for metformin repartitioning from blood cells to plasma (∼0.02 h(-1)) is far slower than the clinical renal elimination rate constant (0.3 h(-1)).,Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),1/[h],∼0.02,62694,DB00331,Metformin
,26062557,renal elimination rate constant,The rate constant for metformin repartitioning from blood cells to plasma (∼0.02 h(-1)) is far slower than the clinical renal elimination rate constant (0.3 h(-1)).,Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062557/),1/[h],0.3,62695,DB00331,Metformin
,22865648,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of MFN, RGN and IS occurred at 1.64, 2.21 and 2.15 min, respectively.",LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22865648/),min,3.5,63127,DB00331,Metformin
,27526402,m/,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,130.1,65700,DB00331,Metformin
,27526402,m/,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,60.1,65701,DB00331,Metformin
,27526402,m/z,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,408.3,65702,DB00331,Metformin
,27526402,m/z,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,235.1,65703,DB00331,Metformin
,27526402,recovery,The mean recovery of MET and STG obtained from spiked plasma samples was 82.5% and 90.4% respectively with minimal matrix interference.,LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),%,82.5,65704,DB00331,Metformin
,27526402,recovery,The mean recovery of MET and STG obtained from spiked plasma samples was 82.5% and 90.4% respectively with minimal matrix interference.,LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),%,90.4,65705,DB00331,Metformin
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],50.8,65727,DB00331,Metformin
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],100.3,65728,DB00331,Metformin
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],177.69,65729,DB00331,Metformin
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],246.2,65730,DB00331,Metformin
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],352.5,65731,DB00331,Metformin
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,130.27,66236,DB00331,Metformin
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,358.14,66237,DB00331,Metformin
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,206.20,66238,DB00331,Metformin
,17459785,limit of detection (LOD),The limit of detection (LOD) of both metformin and rosiglitazone was 1 ng/ml.,Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),[ng] / [ml],1,66239,DB00331,Metformin
,26191653,AUC,"A trend toward reduced TT4 AUC was observed after metformin ingestion (pre-metformin 3893 ± 568 μg/dL-min, post-metformin 3765 ± 588 μg/dL-min, p = 0.09).",Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26191653/),[μg] / [dl-min],3893,68301,DB00331,Metformin
,26191653,AUC,"A trend toward reduced TT4 AUC was observed after metformin ingestion (pre-metformin 3893 ± 568 μg/dL-min, post-metformin 3765 ± 588 μg/dL-min, p = 0.09).",Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26191653/),[μg] / [dl-min],3765,68302,DB00331,Metformin
,30428337,half-maximal inhibitory concentration (IC50),"The non-everted intestinal sac study showed that berberine inhibited the absorption of metformin, and in transfected Madin-Darby canine kidney (MDCK)-rat organic cation transporter 1 (MDCK-rOCT1), MDCK-rat organic cation transporter 2 (MDCK-rOCT2), and MDCK-rat multidrug and toxin extrusion 1 (MDCK-rMATE1) cells, berberine significantly inhibited metformin transport mediated by OCT1, OCT2, and MATE1 in a concentration-dependent manner with half-maximal inhibitory concentration (IC50) values of 18.8, 1.02, and 10.7 μM, respectively.",Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30428337/),μM,18.8,69009,DB00331,Metformin
,30428337,half-maximal inhibitory concentration (IC50),"The non-everted intestinal sac study showed that berberine inhibited the absorption of metformin, and in transfected Madin-Darby canine kidney (MDCK)-rat organic cation transporter 1 (MDCK-rOCT1), MDCK-rat organic cation transporter 2 (MDCK-rOCT2), and MDCK-rat multidrug and toxin extrusion 1 (MDCK-rMATE1) cells, berberine significantly inhibited metformin transport mediated by OCT1, OCT2, and MATE1 in a concentration-dependent manner with half-maximal inhibitory concentration (IC50) values of 18.8, 1.02, and 10.7 μM, respectively.",Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30428337/),μM,1.02,69010,DB00331,Metformin
,30428337,half-maximal inhibitory concentration (IC50),"The non-everted intestinal sac study showed that berberine inhibited the absorption of metformin, and in transfected Madin-Darby canine kidney (MDCK)-rat organic cation transporter 1 (MDCK-rOCT1), MDCK-rat organic cation transporter 2 (MDCK-rOCT2), and MDCK-rat multidrug and toxin extrusion 1 (MDCK-rMATE1) cells, berberine significantly inhibited metformin transport mediated by OCT1, OCT2, and MATE1 in a concentration-dependent manner with half-maximal inhibitory concentration (IC50) values of 18.8, 1.02, and 10.7 μM, respectively.",Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30428337/),μM,10.7,69011,DB00331,Metformin
,19160803,Cmax,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[mg] / [l],18.95,69103,DB00331,Metformin
,19160803,Cmax,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[mg] / [l],21.76,69104,DB00331,Metformin
,19160803,t1/2,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),min,"1,069.8",69105,DB00331,Metformin
,19160803,t1/2,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),min,"1,767.4",69106,DB00331,Metformin
,19160803,CL/F,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[l] / [kg·min],0.013,69107,DB00331,Metformin
,19160803,CL/F,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[l] / [kg·min],0.008,69108,DB00331,Metformin
,19160803,AUC,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[mg·z] / [l·min],"10,042.1",69109,DB00331,Metformin
,19160803,AUC,"The pharmacokinetic parameter Cmax of the controlling group and the testing group were respectively, 18.95, 21.76 mg x L(-1); t1/2 were 1,069.8, 1,767.4 min, respectively; CL/F were 0.013, 0.008 L x min(-1) x kg(-1); AUC were 10,042.1, 10,712.2 mg z L(-1) x min(-1) respectively.",[Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160803/),[mg·z] / [l·min],"10,712.2",69110,DB00331,Metformin
,15357011,Cmax,"The estimated Cmax, Tmax, CLt/F (apparent clearance), V/F(apparent volume of distribution), and half-life of metformin were 1.42 +/- 0.07 microg/mL, 2.59 +/- 0.18 h, 66.12 +/- 4.6 L/h, 26.63 L, and 1.54 h respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),[μg] / [ml],1.42,72024,DB00331,Metformin
,15357011,half-life,"The estimated Cmax, Tmax, CLt/F (apparent clearance), V/F(apparent volume of distribution), and half-life of metformin were 1.42 +/- 0.07 microg/mL, 2.59 +/- 0.18 h, 66.12 +/- 4.6 L/h, 26.63 L, and 1.54 h respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),h,1.54,72025,DB00331,Metformin
,15357011,concentration at half-maximum inhibition IC50,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),[μg] / [ml],2.26,72026,DB00331,Metformin
,15357011,concentration at half-maximum inhibition IC50,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],83.26,72027,DB00331,Metformin
,15357011,kin,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],83.26,72028,DB00331,Metformin
,15357011,kout,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],0.68,72029,DB00331,Metformin
,11594240,absolute bioavailability,"It is well-absorbed, with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5 hours.",Pharmacokinetics and clinical efficacy of pioglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),%,83,72504,DB00331,Metformin
,11594240,half-life,The half-life is about 9 hours but two active metabolites mainly contribute to the extended glucose-lowering effects.,Pharmacokinetics and clinical efficacy of pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),h,9,72505,DB00331,Metformin
,30119251,AUC,The AUC of metformin was from 2791 ± 382 μg min mL-1 to 4784 ± 767 μg min mL-1.,Involvement of organic cation transporter 2 in the metformin-associated increased lactate levels caused by contrast-induced nephropathy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119251/),[min·μg] / [ml],2791,72671,DB00331,Metformin
,30119251,AUC,The AUC of metformin was from 2791 ± 382 μg min mL-1 to 4784 ± 767 μg min mL-1.,Involvement of organic cation transporter 2 in the metformin-associated increased lactate levels caused by contrast-induced nephropathy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119251/),[min·μg] / [ml],4784,72672,DB00331,Metformin
,31039656,hydrodynamic diameter,The mean hydrodynamic diameter of the formulated vesicles was in the range of 288.7-578 nm.,"Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),nm,288.7-578,73101,DB00331,Metformin
,31039656,EE%,"The EE% varied from 71 ± 1.4% to 89 ± 5.2%, with an optimum EE% of 89 ± 5.2at a lipid ratio of 2/1 stearylamine/cholesterol.","Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),%,71,73102,DB00331,Metformin
,31039656,EE%,"The EE% varied from 71 ± 1.4% to 89 ± 5.2%, with an optimum EE% of 89 ± 5.2at a lipid ratio of 2/1 stearylamine/cholesterol.","Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),%,89,73103,DB00331,Metformin
,31039656,EE%,"The EE% varied from 71 ± 1.4% to 89 ± 5.2%, with an optimum EE% of 89 ± 5.2at a lipid ratio of 2/1 stearylamine/cholesterol.","Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),,89,73104,DB00331,Metformin
,31039656,biological half-life (t1/2),Metformin-loaded sterosomes resulted in a significant increase in biological half-life (t1/2) with a mean value of 7.31 ± 1.04 h compared to 3.99 ± 0.17 h of the solution form.,"Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),h,7.31,73105,DB00331,Metformin
,31039656,biological half-life (t1/2),Metformin-loaded sterosomes resulted in a significant increase in biological half-life (t1/2) with a mean value of 7.31 ± 1.04 h compared to 3.99 ± 0.17 h of the solution form.,"Design, optimization, characterization, and in vivo evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039656/),h,3.99,73106,DB00331,Metformin
,20046712,retention time,The retention time was 4.7 min.,Rapid and Simple RPHPLC Method for the Estimation of Metformin in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20046712/),min,4.7,73133,DB00331,Metformin
,34268884,absorption fraction,The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake.,Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),,0.31,73655,DB00331,Metformin
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,2,73656,DB00331,Metformin
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,3,73657,DB00331,Metformin
,29403791,flow rate,The reconstituted samples were chromatographed on a Alltima HP C18 column by using a 60:40 (v/v) mixture of acetonitrile and 10 mM ammonium acetate (pH 3.0) as the mobile phase at a flow rate of 1.1 mL/min.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),[ml] / [min],1.1,74796,DB00331,Metformin
,29403791,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),min,2.5,74797,DB00331,Metformin
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],46.9,76468,DB00331,Metformin
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],16.6,76469,DB00331,Metformin
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],24.3,76470,DB00331,Metformin
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],244,76471,DB00331,Metformin
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],169,76472,DB00331,Metformin
,24170325,elimination half-life,"Moreover, lansoprazole prolonged the metformin elimination half-life from 3.9 to 4.5 h and decreased its renal clearance by 13 % (P < 0.05).","The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170325/),h,3,76686,DB00331,Metformin
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.25,77927,DB00331,Metformin
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.55,77928,DB00331,Metformin
,27245553,half maximal inhibitory concentration (IC50),"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,26.0,78035,DB00331,Metformin
,27245553,IC50,"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,4.6,78036,DB00331,Metformin
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"28,276",78037,DB00331,Metformin
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"24,691",78038,DB00331,Metformin
,20039777,non-renal clearance (CL(NR)),"After the intravenous administration of both drugs together to male DMIS rats, the time-averaged non-renal clearance (CL(NR)) of metformin was significantly slower (by 33.1%; 10.3 versus 15.4 ml min(-1) kg(-1)) than metformin alone due to the inhibition of hepatic metabolism of metformin by telithromycin via CYP3A1/2.",Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039777/),[ml] / [kg·min],10.3,78141,DB00331,Metformin
,20039777,non-renal clearance (CL(NR)),"After the intravenous administration of both drugs together to male DMIS rats, the time-averaged non-renal clearance (CL(NR)) of metformin was significantly slower (by 33.1%; 10.3 versus 15.4 ml min(-1) kg(-1)) than metformin alone due to the inhibition of hepatic metabolism of metformin by telithromycin via CYP3A1/2.",Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039777/),[ml] / [kg·min],15.4,78142,DB00331,Metformin
,27138025,Cmax,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[ng] / [ml],61.9,79162,DB00331,Metformin
,27138025,Cmax,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[ng] / [ml],43.9,79163,DB00331,Metformin
,27138025,Cmax,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[ng] / [ml],1600,79164,DB00331,Metformin
,27138025,Cmax,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[ng] / [ml],1330,79165,DB00331,Metformin
,27138025,AUC0-t,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[h·ng] / [ml],267,79166,DB00331,Metformin
,27138025,AUC0-t,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[h·ng] / [ml],265,79167,DB00331,Metformin
,27138025,AUC0-t,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[h·ng] / [ml],11 000,79168,DB00331,Metformin
,27138025,AUC0-t,"Dapagliflozin 5 mg and metformin 1000 mg geometric mean Cmax was increased in the fasted versus fed state (61.9 vs 43.9 and 1600 vs 1330 ng/mL, respectively), but AUC0-t was similar (267 and 265 and 11 000 and 10 600 ng · h/mL, respectively).",Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138025/),[h·ng] / [ml],10 600,79169,DB00331,Metformin
,23305245,apparent systemic metformin clearance (CL/F),"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),[l] / [h],74 to 54,80986,DB00331,Metformin
,23305245,renal metformin clearance,"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),[l] / [h],31 to 21,80987,DB00331,Metformin
,23305245,half-life,"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),h,2.7 to 3.6,80988,DB00331,Metformin
,23417334,apparent oral clearance (CL/F),"The values obtained were 102±34.5 L/h for apparent oral clearance (CL/F), 447±214 L for volume of distribution (V d/F), and 3.1±0.9 h for terminal half-life (mean±SD) by non-compartmental analysis.",Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417334/),[l] / [h],102,83649,DB00331,Metformin
,23417334,volume of distribution (V d/F),"The values obtained were 102±34.5 L/h for apparent oral clearance (CL/F), 447±214 L for volume of distribution (V d/F), and 3.1±0.9 h for terminal half-life (mean±SD) by non-compartmental analysis.",Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417334/),l,447,83650,DB00331,Metformin
,23417334,terminal half-life,"The values obtained were 102±34.5 L/h for apparent oral clearance (CL/F), 447±214 L for volume of distribution (V d/F), and 3.1±0.9 h for terminal half-life (mean±SD) by non-compartmental analysis.",Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417334/),h,3.1,83651,DB00331,Metformin
,30706085,Clcrea,Patients' Clcrea ranged from 21.6-155.9 mL/min.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),[ml] / [min],21.6-155.9,85026,DB00331,Metformin
,30706085,elimination half-life (t ½),The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,11.9,85027,DB00331,Metformin
,30706085,elimination half-life (t ½),The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,18.5,85028,DB00331,Metformin
,30706085,capillary blood concentrations,Sitagliptin capillary blood concentrations ranged between 11.12-995.6 ng/mL.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),[ng] / [ml],11.12-995.6,85029,DB00331,Metformin
,30706085,t ½,"Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.",Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,8.4,85030,DB00331,Metformin
,30706085,t ½,"Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.",Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,13.0,85031,DB00331,Metformin
,26337524,half-life (t½ ),"In a study of the oral administration of a single dose of metformin to healthy participants, the estimated half-life (t½ ) for the elimination of the drug from erythrocytes was found to be 23.4 h (compared with 2.7 h for metformin in plasma).",Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337524/),h,23.4,85189,DB00331,Metformin
,26337524,half-life (t½ ),"In a study of the oral administration of a single dose of metformin to healthy participants, the estimated half-life (t½ ) for the elimination of the drug from erythrocytes was found to be 23.4 h (compared with 2.7 h for metformin in plasma).",Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337524/),h,2.7,85190,DB00331,Metformin
,26337524,terminal t½,"The estimated mean terminal t½ for metformin in plasma and erythrocytes was 51.9 and 43.4 h, respectively.",Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337524/),h,51.9,85191,DB00331,Metformin
,26337524,terminal t½,"The estimated mean terminal t½ for metformin in plasma and erythrocytes was 51.9 and 43.4 h, respectively.",Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337524/),h,43.4,85192,DB00331,Metformin
,29534338,peak,Measured metformin concentrations were extremely high with a peak of 292 μg ml-1 at 8 h postingestion.,'Massive' metformin overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[μg] / [ml],292,86082,DB00331,Metformin
,29534338,apparent oral clearance,Pharmacokinetic analysis of metformin concentrations found a reduced apparent oral clearance of 8.2 l h-1 and a half-life of approximately 30 h.,'Massive' metformin overdose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[l] / [h],8.2,86083,DB00331,Metformin
,29534338,half-life,Pharmacokinetic analysis of metformin concentrations found a reduced apparent oral clearance of 8.2 l h-1 and a half-life of approximately 30 h.,'Massive' metformin overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),h,30,86084,DB00331,Metformin
,29534338,apparent oral clearance,"During IHD, the apparent oral clearance increased to 22.2 l h-1 with an approximate half-life of 10 h.",'Massive' metformin overdose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[l] / [h],22.2,86085,DB00331,Metformin
,29534338,half-life,"During IHD, the apparent oral clearance increased to 22.2 l h-1 with an approximate half-life of 10 h.",'Massive' metformin overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),h,10,86086,DB00331,Metformin
,27618606,maximum plasma concentration,Pre-administration of pomegranate significantly reduced metformin maximum plasma concentration from 1410 to 1031 ng/ml.,Pomegranate and licorice juices modulate metformin pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618606/),[ng] / [ml],1410 to 1031,86832,DB00331,Metformin
,34200427,volumes of distribution (VSS),Reported volumes of distribution (VSS) varied appreciably (0.32 to 10.1 L/kg) among species.,Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34200427/),[l] / [kg],0.32 to 10.1,91445,DB00331,Metformin
,19446153,AUC(0-infinity),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],339.5,92060,DB00331,Metformin
,19446153,C(max),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],85.1,92061,DB00331,Metformin
,19446153,AUC(0-infinity)),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],159.2,92062,DB00331,Metformin
,19446153,C(max),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],56.3,92063,DB00331,Metformin
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-3465.6,92064,DB00331,Metformin
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-,92065,DB00331,Metformin
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],4422.2,92066,DB00331,Metformin
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],3457.4,92067,DB00331,Metformin
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],125.5,92068,DB00331,Metformin
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],-1403.8,92069,DB00331,Metformin
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],1843.1,92070,DB00331,Metformin
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],40.2,92253,DB00331,Metformin
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],95.4,92254,DB00331,Metformin
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],14.5,92255,DB00331,Metformin
,27849380,AUC,"Insulin AUC was reduced from baseline with saxagliptin + dapagliflozin (-1,120.4 [-1,633.9 to -606.9] μU/mL) and dapagliflozin + placebo (-1,018.6 [-1550.5 to -486.8] μU/mL) but increased with saxagliptin + placebo (661.2 [131.1 to 1,191.3] μU/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[μu] / [ml],661.2,92256,DB00331,Metformin
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB00331,Metformin
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB00331,Metformin
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB00331,Metformin
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB00331,Metformin
,15018802,total run time,The method has a chromatographic total run time of 3.4 min and was linear within the range 2-2000 ng/ml.,Rapid determination of metformin in human plasma by liquid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018802/),min,3.4,95814,DB00331,Metformin
,15932841,peak,"Excluding this subject, the mean peak and trough serum metformin concentrations were 1.06 mug/mL (range 0.68-1.90 mug/mL) and 0.42 mug/mL (range 0.26-0.51 mug/mL), respectively, whereas the mean peak and trough metformin concentrations in breast milk were 0.42 mug/mL (range 0.38-0.46 mug/mL) and 0.39 mug/mL (range 0.31-0.52 mug/mL), respectively.",Excretion of metformin into breast milk and the effect on nursing infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932841/),[μg] / [ml],1.06,95899,DB00331,Metformin
,15932841,trough serum metformin concentrations,"Excluding this subject, the mean peak and trough serum metformin concentrations were 1.06 mug/mL (range 0.68-1.90 mug/mL) and 0.42 mug/mL (range 0.26-0.51 mug/mL), respectively, whereas the mean peak and trough metformin concentrations in breast milk were 0.42 mug/mL (range 0.38-0.46 mug/mL) and 0.39 mug/mL (range 0.31-0.52 mug/mL), respectively.",Excretion of metformin into breast milk and the effect on nursing infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932841/),[μg] / [ml],0.42,95900,DB00331,Metformin
,15932841,peak,"Excluding this subject, the mean peak and trough serum metformin concentrations were 1.06 mug/mL (range 0.68-1.90 mug/mL) and 0.42 mug/mL (range 0.26-0.51 mug/mL), respectively, whereas the mean peak and trough metformin concentrations in breast milk were 0.42 mug/mL (range 0.38-0.46 mug/mL) and 0.39 mug/mL (range 0.31-0.52 mug/mL), respectively.",Excretion of metformin into breast milk and the effect on nursing infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932841/),[μg] / [ml],0.42,95901,DB00331,Metformin
,15932841,trough metformin concentrations,"Excluding this subject, the mean peak and trough serum metformin concentrations were 1.06 mug/mL (range 0.68-1.90 mug/mL) and 0.42 mug/mL (range 0.26-0.51 mug/mL), respectively, whereas the mean peak and trough metformin concentrations in breast milk were 0.42 mug/mL (range 0.38-0.46 mug/mL) and 0.39 mug/mL (range 0.31-0.52 mug/mL), respectively.",Excretion of metformin into breast milk and the effect on nursing infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932841/),[μg] / [ml],0.39,95902,DB00331,Metformin
,15932841,milk:serum ratio,The mean milk:serum ratio was 0.63 (range 0.36-1.00) and the mean estimated infant dose as a percentage of the mother's weight-adjusted dose was 0.65% (range 0.43-1.08%).,Excretion of metformin into breast milk and the effect on nursing infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932841/),,0.63,95903,DB00331,Metformin
<,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,50,97592,DB00331,Metformin
<,28615288,Jmax,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),[pM] / [(cm)^2·min],50,97593,DB00331,Metformin
>,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,200,97594,DB00331,Metformin
,21989078,trough steady-state metformin plasma concentration,"The mean trough steady-state metformin plasma concentration was estimated to be 576 ng/ml (range, 54–4133 ng/ml, p = 0.55) and correlated to the number of reduced function alleles in OCT1 (none, one or two: 642, 542, 397 ng/ml; P = 0.001).",The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21989078/),[ng] / [ml],576,101221,DB00331,Metformin
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],43.1,102014,DB00331,Metformin
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],45.9,102015,DB00331,Metformin
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],29.0,102016,DB00331,Metformin
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],33.1,102017,DB00331,Metformin
,21690265,Plasma clearance,"Plasma clearance was low in rats (4.04 ml · min(-1) · kg(-1)) and dogs (1.64 ml · min(-1) · kg(-1)), resulting in half-lives of 4.10 and 7.63 h, respectively.","Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),[ml] / [kg·min],4.04,102457,DB00331,Metformin
,21690265,Plasma clearance,"Plasma clearance was low in rats (4.04 ml · min(-1) · kg(-1)) and dogs (1.64 ml · min(-1) · kg(-1)), resulting in half-lives of 4.10 and 7.63 h, respectively.","Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),[ml] / [kg·min],1.64,102458,DB00331,Metformin
,21690265,half-lives,"Plasma clearance was low in rats (4.04 ml · min(-1) · kg(-1)) and dogs (1.64 ml · min(-1) · kg(-1)), resulting in half-lives of 4.10 and 7.63 h, respectively.","Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),h,4.10,102459,DB00331,Metformin
,21690265,half-lives,"Plasma clearance was low in rats (4.04 ml · min(-1) · kg(-1)) and dogs (1.64 ml · min(-1) · kg(-1)), resulting in half-lives of 4.10 and 7.63 h, respectively.","Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),h,7.63,102460,DB00331,Metformin
,21690265,bioavailability,Moderate to good bioavailability in rats (69%) and dogs (94%) was observed after oral dosing.,"Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),%,69,102461,DB00331,Metformin
,21690265,bioavailability,Moderate to good bioavailability in rats (69%) and dogs (94%) was observed after oral dosing.,"Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),%,94,102462,DB00331,Metformin
,21690265,IC(50),Inhibitory effects against the organic cation transporter 2-mediated uptake of [(14)C]metformin by PF-04971729 also were very weak (IC(50) = ∼900 μM).,"Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690265/),μM,∼900,102463,DB00331,Metformin
,17479540,relative bioavailability,"And on the basis of the mean AUC(0-t), AUC(0-infinity) and AUC(ss), the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.",Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479540/),%,107.80,104334,DB00331,Metformin
,17479540,relative bioavailability,"And on the basis of the mean AUC(0-t), AUC(0-infinity) and AUC(ss), the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.",Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479540/),%,111.89,104335,DB00331,Metformin
,17479540,relative bioavailability,"And on the basis of the mean AUC(0-t), AUC(0-infinity) and AUC(ss), the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.",Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479540/),%,110.61,104336,DB00331,Metformin
,30605260,half-maximal inhibition,"Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively.",No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30605260/),[μg] / [ml],5120,104760,DB00331,Metformin
,30605260,half-maximal inhibition,"Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively.",No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30605260/),[μg] / [ml],1300,104761,DB00331,Metformin
,30605260,half-maximal inhibition,"Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively.",No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30605260/),[μg] / [ml],338,104762,DB00331,Metformin
,24009308,T(max),"On average, 1.0% ± 0.1% of the metformin oral dose was present in the liver (liver/plasma ratio = 4.5 ± 0.6) over a pharmacologically relevant dose and time range in mice (10-300 mg/kg; 1.5-2.5 hours; T(max) = 1.4 ± 0.5; bioavailability > 59%).",Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009308/),,1.4,106939,DB00331,Metformin
>,24009308,bioavailability,"On average, 1.0% ± 0.1% of the metformin oral dose was present in the liver (liver/plasma ratio = 4.5 ± 0.6) over a pharmacologically relevant dose and time range in mice (10-300 mg/kg; 1.5-2.5 hours; T(max) = 1.4 ± 0.5; bioavailability > 59%).",Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009308/),%,59,106940,DB00331,Metformin
,24009308,kidney/plasma ratio,"Distribution to the kidneys was not markedly higher, which contained 0.87% ± 0.08% of the oral dose (kidney/plasma ratio = 11.9 ± 1.1).",Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009308/),,11.9,106941,DB00331,Metformin
,24009308,recovery,"In single-pass liver perfusion studies, 2.4% ± 0.3% of the perfused metformin dose was distributed to the liver, which underwent >300-fold greater sinusoidal than biliary excretion during the subsequent drug-free washout perfusion (74.0% ± 39.3% versus 0.222% ± 0.003% recovery of hepatic metformin in perfusate versus bile, respectively).",Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009308/),%,0.222,106942,DB00331,Metformin
,33826656,half-life (T1/2),"Most tissues have a half-life (T1/2) similar to plasma (3.7h) except for the liver and intestine with shorter T1/2 and muscle, kidney, and red blood cells that have longer T1/2.",Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33826656/),h,3.7,107922,DB00331,Metformin
,17331818,run time,"The mobile phase consisted of water-acetonitrile and formic acid (55/45/0.048, v/v/%) and the run time was 3 min.",Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),min,3,108202,DB00331,Metformin
,17331818,C(max),The method was applied to determine the pharmacokinetic parameters: C(max) (1667.25 ng/mL) and T(max) (3.89 h).,Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),[ng] / [ml],1667.25,108203,DB00331,Metformin
,17331818,T(max),The method was applied to determine the pharmacokinetic parameters: C(max) (1667.25 ng/mL) and T(max) (3.89 h).,Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),h,3.89,108204,DB00331,Metformin
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,2.9,110571,DB00331,Metformin
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,21,110572,DB00331,Metformin
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],442,110573,DB00331,Metformin
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],94,110574,DB00331,Metformin
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],30.6,111715,DB00331,Metformin
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],33.1,111716,DB00331,Metformin
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],37.1,111717,DB00331,Metformin
,22072731,plasma unbound concentrations,"They were 95 to 146 μM for hOCT2, providing at most 10% inhibition based on its clinically reported plasma unbound concentrations (3.6-7.8 μM).","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,3.6-7.8,112143,DB00331,Metformin
,22072731,K(i),"In contrast, cimetidine is a potent inhibitor of MATE1 and MATE2-K with K(i) values (μM) of 1.1 to 3.8 and 2.1 to 6.9, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,1.1 to 3.8,112144,DB00331,Metformin
,22072731,K(i),"In contrast, cimetidine is a potent inhibitor of MATE1 and MATE2-K with K(i) values (μM) of 1.1 to 3.8 and 2.1 to 6.9, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,2.1 to 6.9,112145,DB00331,Metformin
,22072731,plasma unbound concentration,"Cimetidine was administered to mice by a constant infusion to achieve a plasma unbound concentration of 21.6 μM to examine its effect on the renal disposition of Mate1 probes (metformin, TEA, and cephalexin) in vivo.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,21.6,112146,DB00331,Metformin
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],49,112147,DB00331,Metformin
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],23,112148,DB00331,Metformin
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],11,112149,DB00331,Metformin
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],6.6,112150,DB00331,Metformin
,29318219,observed trough concentrations,"Median (interquartile range) observed trough concentrations of metformin in cohorts 1, 2, and 3 were 0.083 (0.121) mg/l, 0.239 (0.603) mg/l, and 1.930 (3.110) mg/l, respectively.",Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318219/),[mg] / [l],0.083,113462,DB00331,Metformin
,29318219,observed trough concentrations,"Median (interquartile range) observed trough concentrations of metformin in cohorts 1, 2, and 3 were 0.083 (0.121) mg/l, 0.239 (0.603) mg/l, and 1.930 (3.110) mg/l, respectively.",Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318219/),[mg] / [l],0.239,113463,DB00331,Metformin
,29318219,observed trough concentrations,"Median (interquartile range) observed trough concentrations of metformin in cohorts 1, 2, and 3 were 0.083 (0.121) mg/l, 0.239 (0.603) mg/l, and 1.930 (3.110) mg/l, respectively.",Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318219/),[mg] / [l],1.930,113464,DB00331,Metformin
,30574864,AUClast,"The corresponding values of AUClast were 0.97 (0.93 - 1.01), 1.00 (0.97 - 1.04), and 1.00 (0.95 - 1.05), respectively.",Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574864/),,0.97,114289,DB00331,Metformin
,30574864,AUClast,"The corresponding values of AUClast were 0.97 (0.93 - 1.01), 1.00 (0.97 - 1.04), and 1.00 (0.95 - 1.05), respectively.",Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574864/),,0,114290,DB00331,Metformin
,30574864,AUClast,"The corresponding values of AUClast were 0.97 (0.93 - 1.01), 1.00 (0.97 - 1.04), and 1.00 (0.95 - 1.05), respectively.",Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574864/),,1.00,114291,DB00331,Metformin
,30574864,AUClast,"The corresponding values of AUClast were 0.97 (0.93 - 1.01), 1.00 (0.97 - 1.04), and 1.00 (0.95 - 1.05), respectively.",Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574864/),,1.00,114292,DB00331,Metformin
,26187926,flow rate,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),[ml] / [min],1.0,116281,DB00331,Metformin
,26187926,total run time,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),min,8.5,116282,DB00331,Metformin
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,130.1,116283,DB00331,Metformin
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,60.2,116284,DB00331,Metformin
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,268.2,116285,DB00331,Metformin
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,116.1,116286,DB00331,Metformin
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,284.2,116287,DB00331,Metformin
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,254.2,116288,DB00331,Metformin
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,152.3,116289,DB00331,Metformin
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,110.1,116290,DB00331,Metformin
,33799652,entrapment yield,The entrapment yield of metformin hydrochloride (MH) in the prepared lipid vesicles was 40.12%.,Potential Enhancement of Metformin Hydrochloride in Lipid Vesicles Targeting Therapeutic Efficacy in Diabetic Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799652/),%,40.12,117188,DB00331,Metformin
,25316572,urinary excretion,"Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities.",Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316572/),%,1,120234,DB00331,Metformin
,25920679,bioavailability,"After oral doses, a significantly lower bioavailability was observed in knockout compared with wild-type mice (0.27 versus 0.58, P < 0.001).",Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920679/),,0.27,128933,DB00331,Metformin
,25920679,bioavailability,"After oral doses, a significantly lower bioavailability was observed in knockout compared with wild-type mice (0.27 versus 0.58, P < 0.001).",Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920679/),,0.58,128934,DB00331,Metformin
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00331,Metformin
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00331,Metformin
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00331,Metformin
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00331,Metformin
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00331,Metformin
,22763773,flow rate,"After one-step protein precipitation of 200 μL plasma with methanol, metformin, glipizide and IS were separated on a Kromasil Phenyl column (4.6 × 150 mm, 5 µm) at 40°C with an isocratic mobile phase consisting of methanol-10 mmol/L ammonium acetate (75:25, v/v) at a flow rate of 0.35 mL/min.",Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763773/),[ml] / [min],0.35,129770,DB00331,Metformin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,243,129954,DB00331,Metformin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,553,129955,DB00331,Metformin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,15,129956,DB00331,Metformin
,14967537,area under the curve (AUC),"The pharmacokinetics of metformin from the mucoadhesive dosage forms indicated that for metformin alone, the area under the curve (AUC) values were 125.6 and 135.6 mgh/ml at 200 and 400 mg/kg BW, respectively.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),[mgh] / [ml],125.6,134367,DB00331,Metformin
,14967537,area under the curve (AUC),"The pharmacokinetics of metformin from the mucoadhesive dosage forms indicated that for metformin alone, the area under the curve (AUC) values were 125.6 and 135.6 mgh/ml at 200 and 400 mg/kg BW, respectively.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),[mgh] / [ml],135.6,134368,DB00331,Metformin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,102.4,134369,DB00331,Metformin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,150.2,134370,DB00331,Metformin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,59.9,134371,DB00331,Metformin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,80.4,134372,DB00331,Metformin
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00331,Metformin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00331,Metformin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00331,Metformin
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,152,136188,DB00331,Metformin
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,154,136189,DB00331,Metformin
,22242459,flow-rate,"After a single plasma protein precipitation with methanol, gabapentin and metformin (internal standard) were chromatographed on a Inertsil ODS-3 column (50 mm x 2.1 mm ID, 3 microm) with mobile phase consisting of methanol-0.2% formic acid aqueous solution (80:20, v/v) at a flow-rate of 0.2 mL x min(-1).",[LC-MS/MS method for quantification and pharmacokinetic study of gabapentin in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242459/),[ml] / [min],0.2,136754,DB00331,Metformin
,22242459,run time,The run time was 2.2 min.,[LC-MS/MS method for quantification and pharmacokinetic study of gabapentin in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242459/),min,2.2,136755,DB00331,Metformin
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB00331,Metformin
,22257580,time to reach maximum concentration,The SR formulation showed a delay in the time to reach maximum concentration for metformin from 1.0 - 4.0 h to 4.0 - 8.0 h and a decreased AUC24 value; the geometric mean ratio for metformin AUC24 was 0.87 (0.74 - 1.03) for Treatment relative to Reference 1 and 0.75 (0.63 - 0.88) for Treatment relative to Reference 2.,Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257580/),h,1.0 - 4.0,140503,DB00331,Metformin
,22257580,time to reach maximum concentration,The SR formulation showed a delay in the time to reach maximum concentration for metformin from 1.0 - 4.0 h to 4.0 - 8.0 h and a decreased AUC24 value; the geometric mean ratio for metformin AUC24 was 0.87 (0.74 - 1.03) for Treatment relative to Reference 1 and 0.75 (0.63 - 0.88) for Treatment relative to Reference 2.,Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257580/),h,4.0 - 8.0,140504,DB00331,Metformin
,21646436,IC(50),"NBuPy-Cl, Bmim-Cl, and BmPy-Cl displayed strong inhibitory effects on these transporters (IC(50) = 0.2-8.5 μM).",Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646436/),μM,0.2-8.5,140968,DB00331,Metformin
,21646436,IC(50),"The IC(50) values were 0.1, 3.8, 14, and 671 μM (hexyl-, butyl-, and ethyl-pyridinium and pyridinium chloride) for rOCT2-mediated metformin transport.",Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646436/),μM,0.1,140969,DB00331,Metformin
,21646436,IC(50),"The IC(50) values were 0.1, 3.8, 14, and 671 μM (hexyl-, butyl-, and ethyl-pyridinium and pyridinium chloride) for rOCT2-mediated metformin transport.",Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646436/),μM,3.8,140970,DB00331,Metformin
,21646436,IC(50),"The IC(50) values were 0.1, 3.8, 14, and 671 μM (hexyl-, butyl-, and ethyl-pyridinium and pyridinium chloride) for rOCT2-mediated metformin transport.",Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646436/),μM,14,140971,DB00331,Metformin
,21646436,IC(50),"The IC(50) values were 0.1, 3.8, 14, and 671 μM (hexyl-, butyl-, and ethyl-pyridinium and pyridinium chloride) for rOCT2-mediated metformin transport.",Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646436/),μM,671,140972,DB00331,Metformin
,28725138,Peff,The optimized Peff ranged 1.44-68.3 × 10-4 cm/s for the drugs under investigation.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),[cm] / [s],1.44-68.3 × 10-4,142143,DB00331,Metformin
,28725138,Saliva/plasma concentrations ratios,Saliva/plasma concentrations ratios ranged 0.17-1.5.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),,0.17-1.5,142144,DB00331,Metformin
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],8.78,142481,DB00331,Metformin
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],7.68,142482,DB00331,Metformin
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],6.32,142483,DB00331,Metformin
,34120651,AUC,"Day 1, for AUC values of remogliflozin etabonate and its metabolites were all very close to 1, indicating no accumulation in plasma concentrations of remogliflozin etabonate and its metabolites.",Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34120651/),,1,143294,DB00331,Metformin
,25876759,cumulative urinary excretion,"However, when metformin was orally administered at the dose of 500 mg/kg, the cumulative urinary excretion and renal tissue-to-plasma concentration ratio of metformin in female rats (26,689 ± 1266 μg and 2.96 ± 0.47 mL/g, respectively) were markedly lowered compared to that of male rats (32,949 ± 1384 μg and 4.20 ± 0.31 mL/g, respectively), and the plasma concentration of metformin in female rats (55.9 ± 4.5 μg/mL) was significantly increased compared to that of male rats (43.5 ± 3.1 μg/mL) at 2 h after oral administration.",Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25876759/),μg,"26,689",143577,DB00331,Metformin
,25876759,cumulative urinary excretion,"However, when metformin was orally administered at the dose of 500 mg/kg, the cumulative urinary excretion and renal tissue-to-plasma concentration ratio of metformin in female rats (26,689 ± 1266 μg and 2.96 ± 0.47 mL/g, respectively) were markedly lowered compared to that of male rats (32,949 ± 1384 μg and 4.20 ± 0.31 mL/g, respectively), and the plasma concentration of metformin in female rats (55.9 ± 4.5 μg/mL) was significantly increased compared to that of male rats (43.5 ± 3.1 μg/mL) at 2 h after oral administration.",Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25876759/),μg,"32,949",143578,DB00331,Metformin
,25876759,renal tissue-to-plasma concentration ratio,"However, when metformin was orally administered at the dose of 500 mg/kg, the cumulative urinary excretion and renal tissue-to-plasma concentration ratio of metformin in female rats (26,689 ± 1266 μg and 2.96 ± 0.47 mL/g, respectively) were markedly lowered compared to that of male rats (32,949 ± 1384 μg and 4.20 ± 0.31 mL/g, respectively), and the plasma concentration of metformin in female rats (55.9 ± 4.5 μg/mL) was significantly increased compared to that of male rats (43.5 ± 3.1 μg/mL) at 2 h after oral administration.",Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25876759/),[ml] / [g],2.96,143579,DB00331,Metformin
,25876759,renal tissue-to-plasma concentration ratio,"However, when metformin was orally administered at the dose of 500 mg/kg, the cumulative urinary excretion and renal tissue-to-plasma concentration ratio of metformin in female rats (26,689 ± 1266 μg and 2.96 ± 0.47 mL/g, respectively) were markedly lowered compared to that of male rats (32,949 ± 1384 μg and 4.20 ± 0.31 mL/g, respectively), and the plasma concentration of metformin in female rats (55.9 ± 4.5 μg/mL) was significantly increased compared to that of male rats (43.5 ± 3.1 μg/mL) at 2 h after oral administration.",Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25876759/),[ml] / [g],4.20,143580,DB00331,Metformin
,27216492,AUC0-t ratio,"In the evaluable population, all treatments produced similar significant reductions in fasting glucose (median reduction range, -0.67 to -0.81 mmol/l across treatments) and postprandial glucose (Day 5 to baseline AUC0-t ratio = 0.9 for all three treatments) and increases in gut hormones (Day 5 to baseline AUC0-t ratio range: 1.6-1.9 for GLP-1 and 1.4-1.5 for PYY) despite an almost 60% reduction in systemic metformin exposure for 500 mg Metformin DR compared with Metformin IR.",Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216492/),,0.9,143654,DB00331,Metformin
,27216492,AUC0-t ratio,"In the evaluable population, all treatments produced similar significant reductions in fasting glucose (median reduction range, -0.67 to -0.81 mmol/l across treatments) and postprandial glucose (Day 5 to baseline AUC0-t ratio = 0.9 for all three treatments) and increases in gut hormones (Day 5 to baseline AUC0-t ratio range: 1.6-1.9 for GLP-1 and 1.4-1.5 for PYY) despite an almost 60% reduction in systemic metformin exposure for 500 mg Metformin DR compared with Metformin IR.",Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216492/),,1.6-1.9,143655,DB00331,Metformin
,27216492,AUC0-t ratio,"In the evaluable population, all treatments produced similar significant reductions in fasting glucose (median reduction range, -0.67 to -0.81 mmol/l across treatments) and postprandial glucose (Day 5 to baseline AUC0-t ratio = 0.9 for all three treatments) and increases in gut hormones (Day 5 to baseline AUC0-t ratio range: 1.6-1.9 for GLP-1 and 1.4-1.5 for PYY) despite an almost 60% reduction in systemic metformin exposure for 500 mg Metformin DR compared with Metformin IR.",Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216492/),,1.4-1.5,143656,DB00331,Metformin
,34097256,renal clearance,The mean renal clearance of metformin was similar following metformin administered alone (34.2 L/h) compared to metformin coadministered with OM (32.9 L/h).,"Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34097256/),[l] / [h],34.2,143797,DB00331,Metformin
,34097256,renal clearance,The mean renal clearance of metformin was similar following metformin administered alone (34.2 L/h) compared to metformin coadministered with OM (32.9 L/h).,"Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34097256/),[l] / [h],32.9,143798,DB00331,Metformin
,8743335,absolute oral bioavailability,"Metformin has an absolute oral bioavailability of 40 to 60%, and gastrointestinal absorption is apparently complete within 6 hours of ingestion.",Clinical pharmacokinetics of metformin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743335/),%,40 to 60,147787,DB00331,Metformin
,8743335,plasma elimination half-life,Metformin undergoes renal excretion and has a mean plasma elimination half-life after oral administration of between 4.0 and 8.7 hours.,Clinical pharmacokinetics of metformin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743335/),h,4.0 and 8.7,147788,DB00331,Metformin
,20919907,elimination half-life (t1/2),"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),h,11.7,148625,DB00331,Metformin
,20919907,maxima plasma concentration,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ng] / [ml],748,148626,DB00331,Metformin
,20919907,area under the curve,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[h·μg] / [ml],355,148627,DB00331,Metformin
,20919907,apparent clearance,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ml] / [kg·min],90.6,148628,DB00331,Metformin
,20919907,Css,The Css was 122±22 ng/mL.,Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ng] / [ml],122,148629,DB00331,Metformin
,21478461,AUC glucose levels,"Gastric bypass patients had significantly lower AUC glucose levels over 8 h compared with control subjects (35.8 vs. 41.7 μg/mL/h; 5.9 [3.1-8.8]), but this was likely a result of differences in baseline fasting glucose and not metformin absorption.",Effect of gastric bypass surgery on the absorption and bioavailability of metformin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21478461/),[μg] / [h·ml],35.8,149648,DB00331,Metformin
,21478461,AUC glucose levels,"Gastric bypass patients had significantly lower AUC glucose levels over 8 h compared with control subjects (35.8 vs. 41.7 μg/mL/h; 5.9 [3.1-8.8]), but this was likely a result of differences in baseline fasting glucose and not metformin absorption.",Effect of gastric bypass surgery on the absorption and bioavailability of metformin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21478461/),[μg] / [h·ml],41.7,149649,DB00331,Metformin
,32816871,clearance,"During NMP of porcine kidneys, metformin clearance peaked at 90 min of NMP (18.2±13.7 mL/min/100 g).",Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816871/),[ml] / [100·g·min],18.2,150199,DB00331,Metformin
,32816871,Michaelis-Menten constant,This observation can be explained by saturation of metformin transporters with a Michaelis-Menten constant (95% CI) of 23.0 (10.0 to 52.3) mg/L.,Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816871/),[mg] / [l],23.0,150200,DB00331,Metformin
,8490112,Cmax,Mean (+/- SD) Cmax was 682.1 (160.6) ng ml-1 at a mean (+/- SD) tmax of 2.4 (0.93) h.,Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490112/),[ng] / [ml],682.1,151109,DB00331,Metformin
,8490112,tmax,Mean (+/- SD) Cmax was 682.1 (160.6) ng ml-1 at a mean (+/- SD) tmax of 2.4 (0.93) h.,Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490112/),h,2.4,151110,DB00331,Metformin
,8490112,half-life,Overall elimination was monoexponential with a mean (+/- SD) half-life of 3.16 (0.47) h.,Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490112/),h,3.16,151111,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.9,152383,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],10.4,152384,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],11.9,152385,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],2.4,152386,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.3,152387,DB00331,Metformin
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.0,152388,DB00331,Metformin
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],13.9,152389,DB00331,Metformin
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.6,152390,DB00331,Metformin
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.9,152391,DB00331,Metformin
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],7.2,152392,DB00331,Metformin
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],1.5,152393,DB00331,Metformin
,19142906,LOD,"The linear range of the CE method for the determination of metformin in plasma was over the range of 0.1-2.0 mug/mL; the LOD of the drug in plasma (S/N = 3; injection 10 kV, 100 s) was 30 ng/mL.",CE with direct sample injection for the determination of metformin in plasma for type 2 diabetic mellitus: An adequate alternative to HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142906/),,3,153577,DB00331,Metformin
,19142906,S/N,"The linear range of the CE method for the determination of metformin in plasma was over the range of 0.1-2.0 mug/mL; the LOD of the drug in plasma (S/N = 3; injection 10 kV, 100 s) was 30 ng/mL.",CE with direct sample injection for the determination of metformin in plasma for type 2 diabetic mellitus: An adequate alternative to HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142906/),,3,153578,DB00331,Metformin
,19142906,S/N,"The linear range of the CE method for the determination of metformin in plasma was over the range of 0.1-2.0 mug/mL; the LOD of the drug in plasma (S/N = 3; injection 10 kV, 100 s) was 30 ng/mL.",CE with direct sample injection for the determination of metformin in plasma for type 2 diabetic mellitus: An adequate alternative to HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142906/),[ng] / [ml],30,153579,DB00331,Metformin
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00331,Metformin
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00331,Metformin
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00331,Metformin
,29748932,oral clearance (CL/F),"In the model, oral clearance (CL/F) of metformin (1.17 l/min [relative standard error of 6%]) increased significantly with TBW (p < 0.01).",Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748932/),[l] / [min],1.17,156220,DB00331,Metformin
,29748932,CL/F,The CL/F of metformin in obese adolescents (1.17 l/min) is larger than that in non-obese children (0.55 l/min) and similar to that in adults (1.3 l/min) as reported in the literature.,Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748932/),[l] / [min],1.17,156221,DB00331,Metformin
,29748932,CL/F,The CL/F of metformin in obese adolescents (1.17 l/min) is larger than that in non-obese children (0.55 l/min) and similar to that in adults (1.3 l/min) as reported in the literature.,Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748932/),[l] / [min],0.55,156222,DB00331,Metformin
,29748932,CL/F,The CL/F of metformin in obese adolescents (1.17 l/min) is larger than that in non-obese children (0.55 l/min) and similar to that in adults (1.3 l/min) as reported in the literature.,Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748932/),[l] / [min],1.3,156223,DB00331,Metformin
,20110017,T(max),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,1.75,158946,DB00331,Metformin
,20110017,T(max),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,2.0,158947,DB00331,Metformin
,20110017,t(1/2),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,8.2,158948,DB00331,Metformin
,20110017,t(1/2),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,8.5,158949,DB00331,Metformin
,20110017,dose-normalized Cmax,"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[ng] / [mg·ml],168.2,158950,DB00331,Metformin
,20110017,dose-normalized Cmax,"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[ng] / [mg·ml],149.9,158951,DB00331,Metformin
,20110017,dose-normalized AUC(last),"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[h·ng] / [mg·ml],681.5,158952,DB00331,Metformin
,20110017,dose-normalized AUC(last),"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[h·ng] / [mg·ml],635.8,158953,DB00331,Metformin
,30914361,droplets,"In the optimized formulation, the mean droplets size, polydispersity index and encapsulation efficiency of the composite were 386.5 nm, 0.219 and 87.26%, respectively.","Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30914361/),nm,386.5,159034,DB00331,Metformin
,30914361,polydispersity index,"In the optimized formulation, the mean droplets size, polydispersity index and encapsulation efficiency of the composite were 386.5 nm, 0.219 and 87.26%, respectively.","Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30914361/),%,0.219,159035,DB00331,Metformin
,30914361,en,"In the optimized formulation, the mean droplets size, polydispersity index and encapsulation efficiency of the composite were 386.5 nm, 0.219 and 87.26%, respectively.","Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30914361/),%,0.219,159036,DB00331,Metformin
,30914361,en,"In the optimized formulation, the mean droplets size, polydispersity index and encapsulation efficiency of the composite were 386.5 nm, 0.219 and 87.26%, respectively.","Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30914361/),%,87.26,159037,DB00331,Metformin
,22762856,Cmax,"For the test formulation, the mean (SD) pharmacokinetic parameters of Cmax and AUC(0-24) were 1,691 (476.7) μg/ ml and 11,081 (2,804.5) mg×h/ml, respectively.","A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762856/),[μg] / [ml],"1,691",159739,DB00331,Metformin
,22762856,AUC(0-24),"For the test formulation, the mean (SD) pharmacokinetic parameters of Cmax and AUC(0-24) were 1,691 (476.7) μg/ ml and 11,081 (2,804.5) mg×h/ml, respectively.","A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762856/),[h·mg] / [ml],"11,081",159740,DB00331,Metformin
,22762856,C(max),"For the reference formulation, the mean (SD) pharmacokinetic parameters of C(max) and AUC(0-24) were 1,749 (494.4) mg/ml and 11,814 (3,344.2) mg×h/ml, respectively.","A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762856/),[mg] / [ml],"1,749",159741,DB00331,Metformin
,22762856,AUC(0-24),"For the reference formulation, the mean (SD) pharmacokinetic parameters of C(max) and AUC(0-24) were 1,749 (494.4) mg/ml and 11,814 (3,344.2) mg×h/ml, respectively.","A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762856/),[h·mg] / [ml],"11,814",159742,DB00331,Metformin
,25939711,AUC(0-12),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[h·ng] / [l],0,161443,DB00331,Metformin
,25939711,AUC(0-12),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[h·ng] / [l],1,161444,DB00331,Metformin
,25939711,AUC(0-12),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[h·ng] / [l],14,161445,DB00331,Metformin
,25939711,AUC(0-12),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[h·ng] / [l],13,161446,DB00331,Metformin
,25939711,C(max),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[ng] / [ml],0,161447,DB00331,Metformin
,25939711,C(max),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[ng] / [ml],2192,161448,DB00331,Metformin
,25939711,C(max),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[ng] / [ml],1934,161449,DB00331,Metformin
,25939711,C(max),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[ng] / [ml],2233,161450,DB00331,Metformin
,25939711,Cl(renal),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[l] / [h],0,161451,DB00331,Metformin
,25939711,Cl(renal),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[l] / [h],31,161452,DB00331,Metformin
,25939711,Cl(renal),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[l] / [h],28,161453,DB00331,Metformin
,25939711,Cl(renal),"Neither AUC(0-12), C(max) nor Cl(renal) were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC(0-12): 0, 1, 2: 14, 13 and 14 h ng/L (P = 0.61)); (C(max): 0, 1, 2: 2192, 1934 and 2233 ng/mL, (P = 0.26)) and (Cl(renal): 0, 1, 2: 31, 28 and 30 L/h (P = 0.57)) CONCLUSIONS: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.",Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939711/),[l] / [h],30,161454,DB00331,Metformin
,25291501,la,"Median lactate concentrations were also similar [1.55 (1.20-1.88) vs. 1.60 (1.35-2.10) mmol l(-1) ] for Indigenous and non-Indigenous patients, respectively.",The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25291501/),[mM] / [l],1.55,162488,DB00331,Metformin
,25291501,la,"Median lactate concentrations were also similar [1.55 (1.20-1.88) vs. 1.60 (1.35-2.10) mmol l(-1) ] for Indigenous and non-Indigenous patients, respectively.",The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25291501/),[mM] / [l],1.60,162489,DB00331,Metformin
,25291501,vitamin B12,The median vitamin B12 was 306 pmol l(-1) (range 105-920 pmol l(-1) ) for the Indigenous patients.,The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25291501/),[pM] / [l],306,162490,DB00331,Metformin
,23652408,renal clearance,"Among the 45 individuals who participated in the metformin pharmacokinetic study, 12 healthy Koreans who were homozygous for haplotype 1 or 2 showed a significant increase in renal clearance [539 ± 76 (reference group) vs. 633 ± 102 (variant group) ml/min; P=0.006] and secretion clearance [439 ± 81 (reference group) vs. 531 ± 102 (variant group) ml/min; P=0.007] of metformin compared with that shown by the reference group.",Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23652408/),[ml] / [min],539,164481,DB00331,Metformin
,23652408,renal clearance,"Among the 45 individuals who participated in the metformin pharmacokinetic study, 12 healthy Koreans who were homozygous for haplotype 1 or 2 showed a significant increase in renal clearance [539 ± 76 (reference group) vs. 633 ± 102 (variant group) ml/min; P=0.006] and secretion clearance [439 ± 81 (reference group) vs. 531 ± 102 (variant group) ml/min; P=0.007] of metformin compared with that shown by the reference group.",Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23652408/),[ml] / [min],633,164482,DB00331,Metformin
,23652408,secretion clearance,"Among the 45 individuals who participated in the metformin pharmacokinetic study, 12 healthy Koreans who were homozygous for haplotype 1 or 2 showed a significant increase in renal clearance [539 ± 76 (reference group) vs. 633 ± 102 (variant group) ml/min; P=0.006] and secretion clearance [439 ± 81 (reference group) vs. 531 ± 102 (variant group) ml/min; P=0.007] of metformin compared with that shown by the reference group.",Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23652408/),[ml] / [min],439,164483,DB00331,Metformin
,23652408,secretion clearance,"Among the 45 individuals who participated in the metformin pharmacokinetic study, 12 healthy Koreans who were homozygous for haplotype 1 or 2 showed a significant increase in renal clearance [539 ± 76 (reference group) vs. 633 ± 102 (variant group) ml/min; P=0.006] and secretion clearance [439 ± 81 (reference group) vs. 531 ± 102 (variant group) ml/min; P=0.007] of metformin compared with that shown by the reference group.",Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23652408/),[ml] / [min],531,164484,DB00331,Metformin
,34102842,IC50,"The inhibitory effects of polymeric micelles on the hOCT1 isoform were the most pronounced, with the lowest IC50 values ranging from 0.106 to 0.280 mg/mL.",mPEG2k-PCLx Polymeric Micelles Influence Pharmacokinetics and Hypoglycemic Efficacy of Metformin through Inhibition of Organic Cation Transporters in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34102842/),[mg] / [ml],0.106 to 0.280,165940,DB00331,Metformin
,18721117,relative bioavailability,"In addition, M-ER has demonstrated a nearly linear dose proportionality with a relative bioavailability of highest dose to lowest dose of 80%, whereas with immediate-release metformin the relative bioavailability of the highest dose to the lowest dose is only 58%.",Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721117/),%,80,168644,DB00331,Metformin
,18721117,relative bioavailability,"In addition, M-ER has demonstrated a nearly linear dose proportionality with a relative bioavailability of highest dose to lowest dose of 80%, whereas with immediate-release metformin the relative bioavailability of the highest dose to the lowest dose is only 58%.",Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721117/),%,58,168645,DB00331,Metformin
,15261814,limit of detection,The limit of detection was 250 pg/ml in plasma.,Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantitation of metformin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15261814/),[pg] / [ml],250,170610,DB00331,Metformin
,28945132,half-life,Mean ± SD half-life of metformin following IV administration was 20.4 ± 4.1 hours.,Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945132/),h,20.4,171929,DB00331,Metformin
,28945132,time to maximum serum concentration,The mean time to maximum serum concentration was 2.5 ± 0.4 hours.,Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945132/),h,2.5,171930,DB00331,Metformin
,28945132,systemic clearance,"Mean systemic clearance and volume of distribution were 24.1 ± 7.8 mL/min/kg and 44.8 ± 23.5 L/kg, respectively.",Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945132/),[ml] / [kg·min],24.1,171931,DB00331,Metformin
,28945132,volume of distribution,"Mean systemic clearance and volume of distribution were 24.1 ± 7.8 mL/min/kg and 44.8 ± 23.5 L/kg, respectively.",Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945132/),[l] / [kg],44.8,171932,DB00331,Metformin
,28945132,oral bioavailability,The mean oral bioavailability was 31%.,Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945132/),%,31,171933,DB00331,Metformin
,33181704,apparent clearance,"The mean population pharmacokinetic parameters were apparent clearance 53.0 L/h, apparent volume of distribution 438 L, absorption rate constant 1.4 hour and lag-time 0.91 hour.",Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181704/),[l] / [h],53.0,173293,DB00331,Metformin
,33181704,apparent volume of distribution,"The mean population pharmacokinetic parameters were apparent clearance 53.0 L/h, apparent volume of distribution 438 L, absorption rate constant 1.4 hour and lag-time 0.91 hour.",Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181704/),l,438,173294,DB00331,Metformin
,33181704,absorption rate constant,"The mean population pharmacokinetic parameters were apparent clearance 53.0 L/h, apparent volume of distribution 438 L, absorption rate constant 1.4 hour and lag-time 0.91 hour.",Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181704/),h,1.4,173295,DB00331,Metformin
,33181704,lag-time,"The mean population pharmacokinetic parameters were apparent clearance 53.0 L/h, apparent volume of distribution 438 L, absorption rate constant 1.4 hour and lag-time 0.91 hour.",Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181704/),h,0.91,173296,DB00331,Metformin
,30809967,AUC0-48h,"The area under the plasma concentration-time curves from time 0 to 48 hours (AUC0-48 h ) of CHI was similar following administration alone or with MET (AUC0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89.7%-103.8%), whereas the maximum concentration (Cmax ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (Cmax , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77.%-94.1%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[h·ng] / [ml],12 540,180874,DB00331,Metformin
,30809967,AUC0-48h,"The area under the plasma concentration-time curves from time 0 to 48 hours (AUC0-48 h ) of CHI was similar following administration alone or with MET (AUC0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89.7%-103.8%), whereas the maximum concentration (Cmax ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (Cmax , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77.%-94.1%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[h·ng] / [ml],12 130,180875,DB00331,Metformin
,30809967,Cmax,"The area under the plasma concentration-time curves from time 0 to 48 hours (AUC0-48 h ) of CHI was similar following administration alone or with MET (AUC0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89.7%-103.8%), whereas the maximum concentration (Cmax ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (Cmax , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77.%-94.1%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[ng] / [ml],1620,180876,DB00331,Metformin
,30809967,Cmax,"The area under the plasma concentration-time curves from time 0 to 48 hours (AUC0-48 h ) of CHI was similar following administration alone or with MET (AUC0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89.7%-103.8%), whereas the maximum concentration (Cmax ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (Cmax , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77.%-94.1%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[ng] / [ml],1420,180877,DB00331,Metformin
,30809967,AUC0-48 h,"The MET exposures remained consistent in the absence or presence of CHI (AUC0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99.1%-110.5%; Cmax , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94.2%-110.9%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[h·ng] / [ml],12 570,180878,DB00331,Metformin
,30809967,AUC0-48 h,"The MET exposures remained consistent in the absence or presence of CHI (AUC0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99.1%-110.5%; Cmax , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94.2%-110.9%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[h·ng] / [ml],13 190,180879,DB00331,Metformin
,30809967,Cmax,"The MET exposures remained consistent in the absence or presence of CHI (AUC0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99.1%-110.5%; Cmax , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94.2%-110.9%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[ng] / [ml],1790,180880,DB00331,Metformin
,30809967,Cmax,"The MET exposures remained consistent in the absence or presence of CHI (AUC0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99.1%-110.5%; Cmax , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94.2%-110.9%).","Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809967/),[ng] / [ml],1820,180881,DB00331,Metformin
>,33246050,floating duration time,The floating duration time of HCFT was>24 h.,Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246050/),h,24,181594,DB00331,Metformin
,33246050,relative bioavailability,"Compared with Glucophage® XR, the relative bioavailability of metformin HCFT was 123.81 ± 3.52%.",Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246050/),%,123.81,181595,DB00331,Metformin
,27550216,flow rate,"A mobile phase composed of 0.1 M sodium dodecyl sulfate, 10% 1-propanol and triethylamine (0.3%) in 0.02 M phosphoric acid, adjusted to pH 2.5, was used at a flow rate of 1 ml/min with fluorimetric detection at 450 nm after excitation at 306 nm.",Micellar liquid chromatographic determination of metformin hydrochloride using fluorimetric detection after pre-column derivatization: application to pharmacokinetic parameters in immediate and sustained release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550216/),[ml] / [min],1,183009,DB00331,Metformin
,27550216,limit of quantification,"The proposed method showed high sensitivity with limit of quantification of 0.35 μg/ml and limit of detection of 0.23 μg/ml, being linear from 0.5 to 3.0 μg/ml.",Micellar liquid chromatographic determination of metformin hydrochloride using fluorimetric detection after pre-column derivatization: application to pharmacokinetic parameters in immediate and sustained release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550216/),[μg] / [ml],0.35,183010,DB00331,Metformin
,27550216,limit of detection,"The proposed method showed high sensitivity with limit of quantification of 0.35 μg/ml and limit of detection of 0.23 μg/ml, being linear from 0.5 to 3.0 μg/ml.",Micellar liquid chromatographic determination of metformin hydrochloride using fluorimetric detection after pre-column derivatization: application to pharmacokinetic parameters in immediate and sustained release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550216/),[μg] / [ml],0.23,183011,DB00331,Metformin
,24699418,Percent drug entrapment,Percent drug entrapment of MH was 99.6±0.35% and in vitro floating ability was 11.3±0.47h.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),%,99.6,183504,DB00331,Metformin
,24699418,floating ability,Percent drug entrapment of MH was 99.6±0.35% and in vitro floating ability was 11.3±0.47h.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),h,11.3,183505,DB00331,Metformin
,24699418,en,"While GLB multiparticulates showed entrapment efficiency of 99.8±0.11%, in vitro buoyancy for 11±0.2h and improved solubility and dissolution rate.",Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),%,99.8,183506,DB00331,Metformin
,24699418,f2,Model independent analysis f2 value for GIV was 40 while for M II was 54.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),,40,183507,DB00331,Metformin
,24699418,f2,Model independent analysis f2 value for GIV was 40 while for M II was 54.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),,54,183508,DB00331,Metformin
,20582190,m/z,"The separated products were identified by characteristic peaks and specific fragments peaks in tandem mass spectrometry as m/z 130 to 86 for metformin, m/z 324 to 110 for gliclazide and m/z 206 to 105 for phenformin.",A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582190/),,130,185602,DB00331,Metformin
,20582190,m/z,"The separated products were identified by characteristic peaks and specific fragments peaks in tandem mass spectrometry as m/z 130 to 86 for metformin, m/z 324 to 110 for gliclazide and m/z 206 to 105 for phenformin.",A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582190/),,86,185603,DB00331,Metformin
,20582190,m/,"The separated products were identified by characteristic peaks and specific fragments peaks in tandem mass spectrometry as m/z 130 to 86 for metformin, m/z 324 to 110 for gliclazide and m/z 206 to 105 for phenformin.",A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582190/),,324 to 110,185604,DB00331,Metformin
,20582190,m/,"The separated products were identified by characteristic peaks and specific fragments peaks in tandem mass spectrometry as m/z 130 to 86 for metformin, m/z 324 to 110 for gliclazide and m/z 206 to 105 for phenformin.",A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582190/),,206 to 105,185605,DB00331,Metformin
,2500402,dialysance,"Lastly, metformin dialysance appears satisfactory (68 ml/min) even in the case of relatively low blood flow; this value reached 170 ml/min under good hemodynamic conditions.",Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500402/),[ml] / [min],68,186121,DB00331,Metformin
,2500402,dialysance,"Lastly, metformin dialysance appears satisfactory (68 ml/min) even in the case of relatively low blood flow; this value reached 170 ml/min under good hemodynamic conditions.",Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500402/),[ml] / [min],170,186122,DB00331,Metformin
,26932305,t(max),"The rate of absorption of metformin decreased when administered under fed condition, as reflected by a prolonged t(max) (3 hours in fasted state vs. 4 hours in fed state) and decrease in C(max) by 26%, however, the extent of absorption (AUC(last)) was similar to that in the fasted state.",Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26932305/),h,3,186719,DB00331,Metformin
,26932305,t(max),"The rate of absorption of metformin decreased when administered under fed condition, as reflected by a prolonged t(max) (3 hours in fasted state vs. 4 hours in fed state) and decrease in C(max) by 26%, however, the extent of absorption (AUC(last)) was similar to that in the fasted state.",Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26932305/),h,4,186720,DB00331,Metformin
,15620533,absolute recovery,Mean absolute recovery was 67.0% for metformin.,Development and validation for high selective quantitative determination of metformin in human plasma by cation exchanging with normal-phase LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15620533/),%,67.0,188196,DB00331,Metformin
,25036533,half-life,"For liraglutide 1.8 mg, mean half-life was 12 h, and clearance was 1.7 L/h.","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036533/),h,12,188363,DB00331,Metformin
,25036533,clearance,"For liraglutide 1.8 mg, mean half-life was 12 h, and clearance was 1.7 L/h.","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036533/),[l] / [h],1.7,188364,DB00331,Metformin
,22926933,apparent volume of distribution,"By measuring metformin concentration at different time intervals, we calculated the apparent volume of distribution of metformin at 34.7 L.",Toxicokinetics of metformin-associated lactic acidosis with continuous renal replacement therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22926933/),l,34.7,192227,DB00331,Metformin
,22926933,elimination rate constant,The decline in serum metformin followed single-compartment first-order kinetics with an elimination rate constant of 0.0418/h and a serum half-life of 16.5 h; no metformin rebound was seen after discontinuation of CVVHDF.,Toxicokinetics of metformin-associated lactic acidosis with continuous renal replacement therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22926933/),1/[h],0.0418,192228,DB00331,Metformin
,22926933,serum half-life,The decline in serum metformin followed single-compartment first-order kinetics with an elimination rate constant of 0.0418/h and a serum half-life of 16.5 h; no metformin rebound was seen after discontinuation of CVVHDF.,Toxicokinetics of metformin-associated lactic acidosis with continuous renal replacement therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22926933/),h,16.5,192229,DB00331,Metformin
,31177048,flow rate,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),[ml] / [min],0.5,194137,DB00331,Metformin
,31177048,run time,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),min,14,194138,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,130.1,194139,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,71,194140,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,357.2,194141,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,134.2,194142,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,462.16,194143,DB00331,Metformin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,191.1,194144,DB00331,Metformin
,28971610,permeability,"Whilst all inhibited OCT1, none enhanced metformin's absorptive permeability (~0.5 × 10-6 cm/sec) suggesting that DDI AUC changes are not related to absorption.","Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971610/),[cm] / [s],0.5 × 10-6,196647,DB00331,Metformin
,28451709,oral availability (F),A population pharmacokinetic model was built (NONMEM) in which the oral availability (F) was fixed to 0.55 with an estimated inter-individual variability (IIV).,A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),,0.55,197946,DB00331,Metformin
,28451709,CLR,Mean CLR was 17 L/h (CV 22%) and mean CLNR/F was 1.6 L/h (69%).,A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),[l] / [h],17,197947,DB00331,Metformin
,28451709,CLNR/F,Mean CLR was 17 L/h (CV 22%) and mean CLNR/F was 1.6 L/h (69%).,A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),[l] / [h],1.6,197948,DB00331,Metformin
,28451709,recovery,The median recovery of metformin in urine was 49% (range 19-75%) over a dosage interval.,A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),%,49,197949,DB00331,Metformin
,28451709,AUC0-12,"Target doses (mg/day) of metformin can be reached using CLCR/3 × 100 to obtain median AUC0-12 of 18-26 mg/L/h for metformin IR and AUC0-24 of 38-51 mg/L/h for metformin XR, with Cmax < 5 mg/L.",A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),[mg] / [h·l],18-26,197950,DB00331,Metformin
,28451709,AUC0-24,"Target doses (mg/day) of metformin can be reached using CLCR/3 × 100 to obtain median AUC0-12 of 18-26 mg/L/h for metformin IR and AUC0-24 of 38-51 mg/L/h for metformin XR, with Cmax < 5 mg/L.",A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),[mg] / [h·l],38-51,197951,DB00331,Metformin
<,28451709,Cmax,"Target doses (mg/day) of metformin can be reached using CLCR/3 × 100 to obtain median AUC0-12 of 18-26 mg/L/h for metformin IR and AUC0-24 of 38-51 mg/L/h for metformin XR, with Cmax < 5 mg/L.",A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451709/),[mg] / [l],5,197952,DB00331,Metformin
,27063928,terminal half-life (t1/2 ),The mean terminal half-life (t1/2 ) was 2-3 h.,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063928/),h,2-3,199850,DB00331,Metformin
,33600406,steady-state average concentration,"The dosing strategy was evaluated using simulations from a published metformin pharmacokinetic model to determine the probability of concentrations exceeding those associated with lactic acidosis risk, i.e. a steady-state average concentration of 3 mg/L and a maximum (peak) concentration of 5 mg/L.",Metformin doses to ensure efficacy and safety in patients with reduced kidney function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33600406/),[mg] / [l],3,200437,DB00331,Metformin
,33600406,maximum (peak) concentration,"The dosing strategy was evaluated using simulations from a published metformin pharmacokinetic model to determine the probability of concentrations exceeding those associated with lactic acidosis risk, i.e. a steady-state average concentration of 3 mg/L and a maximum (peak) concentration of 5 mg/L.",Metformin doses to ensure efficacy and safety in patients with reduced kidney function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33600406/),[mg] / [l],5,200438,DB00331,Metformin
,24452520,Saliva/plasma concentration ratios,Saliva/plasma concentration ratios were 0.29-0.39.,Saliva vs. plasma bioequivalence of metformin in humans: validation of class II drugs of the salivary excretion classification system. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452520/),,0.29-0.39,201345,DB00331,Metformin
,19405907,distribution half-life,Mean +/- SD distribution half-life of metformin following IV administration was 24.9 +/- 0.4 minutes with a volume of distribution of 0.3 +/- 0.1 L/kg.,Pharmacokinetics and bioavailability of metformin in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),min,24.9,201538,DB00331,Metformin
,19405907,volume of distribution,Mean +/- SD distribution half-life of metformin following IV administration was 24.9 +/- 0.4 minutes with a volume of distribution of 0.3 +/- 0.1 L/kg.,Pharmacokinetics and bioavailability of metformin in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[l] / [kg],0.3,201539,DB00331,Metformin
,19405907,area under the curve,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],20.9,201540,DB00331,Metformin
,19405907,area under the curves,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],1.6,201541,DB00331,Metformin
,19405907,area under the curves,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],0.8,201542,DB00331,Metformin
,19405907,Bioavailability,Bioavailability was determined to be approximately 7.1 +/- 1.5% in unfed horses and 3.9 +/- 1.0% in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),%,7.1,201543,DB00331,Metformin
,19405907,Bioavailability,Bioavailability was determined to be approximately 7.1 +/- 1.5% in unfed horses and 3.9 +/- 1.0% in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),%,3.9,201544,DB00331,Metformin
,19405907,maximal concentration,The maximal concentration following PO administration in unfed horses was 0.4 +/- 0.1 microg/mL with a time at maximal concentration of 0.9 +/- 0.1 hours.,Pharmacokinetics and bioavailability of metformin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[μg] / [ml],0.4,201545,DB00331,Metformin
,19405907,time at maximal concentration,The maximal concentration following PO administration in unfed horses was 0.4 +/- 0.1 microg/mL with a time at maximal concentration of 0.9 +/- 0.1 hours.,Pharmacokinetics and bioavailability of metformin in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),h,0.9,201546,DB00331,Metformin
,19405907,maximal concentration,"In fed horses, maximal concentration was reduced to 0.3 +/- 0.04 microg/mL with a time at maximal concentration at 1.3 +/- 0.3 hours.",Pharmacokinetics and bioavailability of metformin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[μg] / [ml],0.3,201547,DB00331,Metformin
,19405907,time at maximal concentration,"In fed horses, maximal concentration was reduced to 0.3 +/- 0.04 microg/mL with a time at maximal concentration at 1.3 +/- 0.3 hours.",Pharmacokinetics and bioavailability of metformin in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),h,1.3,201548,DB00331,Metformin
,22372865,oral bioavailability,It is well absorbed from the upper part of gastrointestinal tract and has oral bioavailability of 50% to 60%.,Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372865/),%,50,202147,DB00331,Metformin
,22372865,oral bioavailability,It is well absorbed from the upper part of gastrointestinal tract and has oral bioavailability of 50% to 60%.,Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372865/),%,60,202148,DB00331,Metformin
,22372865,half-life (t(1/2)),The prolongation of half-life (t(1/2)) from 4.5 ± 2.41 h to 14.12 ± 4.81 h indicated extended duration of action.,Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372865/),h,4.5,202149,DB00331,Metformin
,22372865,half-life (t(1/2)),The prolongation of half-life (t(1/2)) from 4.5 ± 2.41 h to 14.12 ± 4.81 h indicated extended duration of action.,Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372865/),h,14.12,202150,DB00331,Metformin
,27059951,half-life,PF-06291874 exposure was approximately dose-proportional with a half-life of ∼19.7-22.7 h.,Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27059951/),h,∼19.7-22.7,202516,DB00331,Metformin
,18031967,flow rate,Mobile phase consisted of a mixture of phosphate buffer and acetonitrile at flow rate of 1.0 ml/min.,HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031967/),[ml] / [min],1.0,203141,DB00331,Metformin
,26079265,limits of detection,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),,3,203527,DB00331,Metformin
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),,3,203528,DB00331,Metformin
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],10,203529,DB00331,Metformin
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],0.16,203530,DB00331,Metformin
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],0.5,203531,DB00331,Metformin
,26079265,retention times,"The retention times were 3.4 and 5.0min for PIO and MET, respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),min,3.4,203532,DB00331,Metformin
,26079265,retention times,"The retention times were 3.4 and 5.0min for PIO and MET, respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),min,5.0,203533,DB00331,Metformin
,22697273,"steady-state maximum plasma concentrations (C(max, ss)","The steady-state maximum plasma concentrations (C(max, ss); mean ± standard deviation) of lobeglitazone and metformin alone were 29.38 ± 5.25 ng/mL and 1661.84 ± 471.88 ng/mL, respectively; the C(max, ss) during co-administration were 27.15 ± 5.75 ng/mL and 1779.92 ± 405.20 ng/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[ng] / [ml],29.38,205009,DB00331,Metformin
,22697273,"steady-state maximum plasma concentrations (C(max, ss)","The steady-state maximum plasma concentrations (C(max, ss); mean ± standard deviation) of lobeglitazone and metformin alone were 29.38 ± 5.25 ng/mL and 1661.84 ± 471.88 ng/mL, respectively; the C(max, ss) during co-administration were 27.15 ± 5.75 ng/mL and 1779.92 ± 405.20 ng/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[ng] / [ml],1661.84,205010,DB00331,Metformin
,22697273,"C(max, ss)","The steady-state maximum plasma concentrations (C(max, ss); mean ± standard deviation) of lobeglitazone and metformin alone were 29.38 ± 5.25 ng/mL and 1661.84 ± 471.88 ng/mL, respectively; the C(max, ss) during co-administration were 27.15 ± 5.75 ng/mL and 1779.92 ± 405.20 ng/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[ng] / [ml],27.15,205011,DB00331,Metformin
,22697273,"C(max, ss)","The steady-state maximum plasma concentrations (C(max, ss); mean ± standard deviation) of lobeglitazone and metformin alone were 29.38 ± 5.25 ng/mL and 1661.84 ± 471.88 ng/mL, respectively; the C(max, ss) during co-administration were 27.15 ± 5.75 ng/mL and 1779.92 ± 405.20 ng/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[ng] / [ml],1779.92,205012,DB00331,Metformin
,22697273,"steady-state areas under the concentration-time curves during the dose interval (AUC(τ, ss)","The steady-state areas under the concentration-time curves during the dose interval (AUC(τ, ss); mean ± standard deviation) of sole administration of lobeglitazone and metformin were 277.53 ± 65.25 ng*h/mL and 9650.27 ± 2089.81 ng*h/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[h·ng] / [ml],277.53,205013,DB00331,Metformin
,22697273,"steady-state areas under the concentration-time curves during the dose interval (AUC(τ, ss)","The steady-state areas under the concentration-time curves during the dose interval (AUC(τ, ss); mean ± standard deviation) of sole administration of lobeglitazone and metformin were 277.53 ± 65.25 ng*h/mL and 9650.27 ± 2089.81 ng*h/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[h·ng] / [ml],9650.27,205014,DB00331,Metformin
,22697273,"AUC(τ, ss)","When lobeglitazone and metformin were administered concomitantly, the AUC(τ, ss) were 257.29 ± 60.61 ng*h/mL and 10600.58 ± 1960.40 ng*h/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[h·ng] / [ml],257.29,205015,DB00331,Metformin
,22697273,"AUC(τ, ss)","When lobeglitazone and metformin were administered concomitantly, the AUC(τ, ss) were 257.29 ± 60.61 ng*h/mL and 10600.58 ± 1960.40 ng*h/mL, respectively.","Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22697273/),[h·ng] / [ml],10600.58,205016,DB00331,Metformin
,16620517,detection limit (peak area),The detection limit (peak area) for the metformin hydrochloride is 0.01 mg/L for a signal-to-noise ratio of 3:1.,Study on a new precolumn derivatization method in the determination of metformin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620517/),[mg] / [l],0.01,208930,DB00331,Metformin
,16620517,signal-to-noise ratio,The detection limit (peak area) for the metformin hydrochloride is 0.01 mg/L for a signal-to-noise ratio of 3:1.,Study on a new precolumn derivatization method in the determination of metformin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620517/),,3:1,208931,DB00331,Metformin
,16620517,detection limit,"In human plasma, the detection limit is 0.02 mg/L.",Study on a new precolumn derivatization method in the determination of metformin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620517/),[mg] / [l],0.02,208932,DB00331,Metformin
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,27.2,209604,DB00331,Metformin
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,6.3,209605,DB00331,Metformin
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,28.9,209606,DB00331,Metformin
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,133.9,209607,DB00331,Metformin
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,29.1,209608,DB00331,Metformin
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,0.61,209609,DB00331,Metformin
,25359200,IC50,"In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 μM, respectively.",Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359200/),μM,7.28,211429,DB00331,Metformin
,25359200,IC50,"In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 μM, respectively.",Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359200/),μM,11.3,211430,DB00331,Metformin
,26825640,Cmax,Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18.3 ± 5.05 versus 15.2 ± 3.23; P = 0.006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0.001).,Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),,18.3,212282,DB00331,Metformin
,26825640,Cmax,Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18.3 ± 5.05 versus 15.2 ± 3.23; P = 0.006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0.001).,Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),,15.2,212283,DB00331,Metformin
,26825640,glucose,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],10.4,212284,DB00331,Metformin
,26825640,glucose,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],11.5,212285,DB00331,Metformin
,26825640,area under the curve,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],10.4,212286,DB00331,Metformin
,26825640,area under the curve,"Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020).",Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825640/),[mmol∙mg] / [l],11.5,212287,DB00331,Metformin
,32605304,AUC ratio,The AUC ratio (IISOR+MET group/IIISOR group) for sorafenib was equal to 0.6.,"Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32605304/),,0.6,214737,DB00331,Metformin
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,58.94,217569,DB00331,Metformin
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,28.03,217570,DB00331,Metformin
,11951812,Tmax (time to maximal plasma concentration),"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,1.25,226840,DB00331,Metformin
,11951812,Tn,"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,0.5,226841,DB00331,Metformin
,27128836,Apparent clearance (CL/F),"Apparent clearance (CL/F) and terminal elimination half-life of dutogliptin were 176 L/h and 12.2 hours, respectively.","Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128836/),[l] / [h],176,227016,DB00331,Metformin
,27128836,terminal elimination half-life,"Apparent clearance (CL/F) and terminal elimination half-life of dutogliptin were 176 L/h and 12.2 hours, respectively.","Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128836/),h,12.2,227017,DB00331,Metformin
,27128836,CL/F,"Typical CL/F values in patients with mild and moderate renal impairment were 121 and 79 L/h, respectively.","Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128836/),[l] / [h],121,227018,DB00331,Metformin
,27128836,CL/F,"Typical CL/F values in patients with mild and moderate renal impairment were 121 and 79 L/h, respectively.","Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128836/),[l] / [h],79,227019,DB00331,Metformin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,473.24,230705,DB00331,Metformin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,419.94,230706,DB00331,Metformin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,130.14,230707,DB00331,Metformin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,60.18,230708,DB00331,Metformin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,340.27,230709,DB00331,Metformin
,16255063,chromatographic running time,"The method had a chromatographic running time of 2.0 min and linear calibration curves over the concentration ranges of 10-10,000 ng ml(-1) for gliclazide and 7.8-4678.9 ng ml(-1) for metformin.",Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255063/),min,2.0,231723,DB00331,Metformin
,16255063,recoveries,The recoveries of the method were found to be 71-104%.,Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255063/),%,71-104,231724,DB00331,Metformin
,16255063,running time,These results indicate that the method was efficient with a very short running time (2.0 min) for metformin and gliclazide compared to the methods reported in the literature.,Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255063/),min,2.0,231725,DB00331,Metformin
,499320,central compartment,"The intravenous dose was distributed to a small central compartment of 9.9 +/- 1.61 (X +/- SE), from which its elimination could be described using three-compartment open model.",Pharmacokinetics of metformin after intravenous and oral administration to man. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499320/),,9.9,232002,DB00331,Metformin
,499320,elimination half-life from plasma,The elimination half-life from plasma was 1.7 +/- 0.1 h.,Pharmacokinetics of metformin after intravenous and oral administration to man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/499320/),h,1.7,232003,DB00331,Metformin
,499320,half-life,Urinary excretion data revealed a quantitatively minor terminal elimination phase with a half-life of 8.9 +/- 0.7 h.,Pharmacokinetics of metformin after intravenous and oral administration to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499320/),h,8.9,232004,DB00331,Metformin
,499320,renal clearance,"After the intravenous dose, metformin was completely excreted unchanged in urine with a renal clearance of 454 +/- 47 ml/min.",Pharmacokinetics of metformin after intravenous and oral administration to man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499320/),[ml] / [min],454,232005,DB00331,Metformin
,499320,bioavailability,The bioavailability of metformin tablets averaged 50--60%.,Pharmacokinetics of metformin after intravenous and oral administration to man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499320/),%,50--60,232006,DB00331,Metformin
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.117,232860,DB00331,Metformin
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.141,232861,DB00331,Metformin
,27019345,AUC ratio,"Assuming competitive inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0 compared to an observed value of 1.46.",Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019345/),,1.0,233900,DB00331,Metformin
,27019345,AUC ratio,"Assuming competitive inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0 compared to an observed value of 1.46.",Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019345/),,1.46,233901,DB00331,Metformin
,16418696,concentrations,"Mean (range) metformin concentrations in cord plasma and in maternal plasma were 0.81 (range, 0.1-2.6) mg/L and 1.2 (range, 0.1-2.9) mg/L, respectively.",Population pharmacokinetics of metformin in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,0.81,234004,DB00331,Metformin
,16418696,concentrations,"Mean (range) metformin concentrations in cord plasma and in maternal plasma were 0.81 (range, 0.1-2.6) mg/L and 1.2 (range, 0.1-2.9) mg/L, respectively.",Population pharmacokinetics of metformin in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,1.2,234005,DB00331,Metformin
,16418696,clearance,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),[l] / [70·h·kg],28,234006,DB00331,Metformin
,16418696,volume of distribution,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),[l] / [70·kg],190,234007,DB00331,Metformin
,16418696,half-life,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),h,5.1,234008,DB00331,Metformin
,16418696,placental partition coefficient,The placental partition coefficient for metformin was 1.07 (36.3%).,Population pharmacokinetics of metformin in late pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,1.07,234009,DB00331,Metformin
,21241070,fractional oral bioavailability (F),The mean ± SD fractional oral bioavailability (F) of metformin is 55 ± 16%.,Clinical pharmacokinetics of metformin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21241070/),%,55,236616,DB00331,Metformin
,21241070,elimination half-life (t(&frac12;)),The elimination half-life (t(&frac12;)) of metformin during multiple dosages in patients with good renal function is approximately 5 hours.,Clinical pharmacokinetics of metformin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21241070/),h,5,236617,DB00331,Metformin
,21241070,renal clearance (CL(R)),"The population mean renal clearance (CL(R)) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function.",Clinical pharmacokinetics of metformin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21241070/),[ml] / [min],510,236618,DB00331,Metformin
,21241070,apparent total clearance after oral administration (CL/F),"The population mean renal clearance (CL(R)) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function.",Clinical pharmacokinetics of metformin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21241070/),[ml] / [min],1140,236619,DB00331,Metformin
,32270440,times to maximum concentration,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,0.7,237662,DB00331,Metformin
,32270440,times to maximum concentration,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,1.0,237663,DB00331,Metformin
,32270440,elimination half-lives,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,8.2,237664,DB00331,Metformin
,32270440,elimination half-lives,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,8.7,237665,DB00331,Metformin
,19433973,first-order elimination half-life,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),h,11.3,239277,DB00331,Metformin
,19433973,clearance,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),[ml] / [min],56.2,239278,DB00331,Metformin
,7818725,peak concentrations (Cmax,"Acarbose induced a significant (P < 0.05) reduction in early (90, 120, 180 min) serum levels, peak concentrations (Cmax: 1.22 +/- 0.14 vs. 1.87 +/- 0.60 mg l-1) and area under the curve of metformin (AUC 0-540 min: 423 +/- 55 vs. 652 +/- 55 mg min l-1), but did not diminish its 24 h urinary excretion.",Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818725/),[mg] / [l],1.22,241311,DB00331,Metformin
,7818725,peak concentrations (Cmax,"Acarbose induced a significant (P < 0.05) reduction in early (90, 120, 180 min) serum levels, peak concentrations (Cmax: 1.22 +/- 0.14 vs. 1.87 +/- 0.60 mg l-1) and area under the curve of metformin (AUC 0-540 min: 423 +/- 55 vs. 652 +/- 55 mg min l-1), but did not diminish its 24 h urinary excretion.",Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818725/),[mg] / [l],1.87,241312,DB00331,Metformin
,7818725,area under the curve of metformin (AUC 0-540 min,"Acarbose induced a significant (P < 0.05) reduction in early (90, 120, 180 min) serum levels, peak concentrations (Cmax: 1.22 +/- 0.14 vs. 1.87 +/- 0.60 mg l-1) and area under the curve of metformin (AUC 0-540 min: 423 +/- 55 vs. 652 +/- 55 mg min l-1), but did not diminish its 24 h urinary excretion.",Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818725/),[mg·min] / [l],423,241313,DB00331,Metformin
,7818725,area under the curve of metformin (AUC 0-540 min,"Acarbose induced a significant (P < 0.05) reduction in early (90, 120, 180 min) serum levels, peak concentrations (Cmax: 1.22 +/- 0.14 vs. 1.87 +/- 0.60 mg l-1) and area under the curve of metformin (AUC 0-540 min: 423 +/- 55 vs. 652 +/- 55 mg min l-1), but did not diminish its 24 h urinary excretion.",Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818725/),[mg·min] / [l],652,241314,DB00331,Metformin
,32055553,renal clearance,"Subjects who had more than one allele of c.883-144A>G single nucleotide polymorphism (SNP) in PMAT gene (rs3889348) showed increased renal clearance of metformin compared to wild-type subjects (814.79 ± 391.73 vs. 619.90 ± 195.43 mL/min, p=0.003), whereas no differences in metformin exposure were observed between the PMAT variant subjects and wild-type subjects.",Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055553/),[ml] / [min],814.79,247520,DB00331,Metformin
,32055553,renal clearance,"Subjects who had more than one allele of c.883-144A>G single nucleotide polymorphism (SNP) in PMAT gene (rs3889348) showed increased renal clearance of metformin compared to wild-type subjects (814.79 ± 391.73 vs. 619.90 ± 195.43 mL/min, p=0.003), whereas no differences in metformin exposure were observed between the PMAT variant subjects and wild-type subjects.",Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055553/),[ml] / [min],619.90,247521,DB00331,Metformin
,32055553,renal clearance,"Similarly, subjects with variant rs316019 SNP in OCT2 showed decreased renal clearance of metformin compared to wild-type subjects (586.01 ± 160.54 vs. 699.13 ± 291.40 mL/min, p=0.048).",Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055553/),[ml] / [min],586.01,247522,DB00331,Metformin
,32055553,renal clearance,"Similarly, subjects with variant rs316019 SNP in OCT2 showed decreased renal clearance of metformin compared to wild-type subjects (586.01 ± 160.54 vs. 699.13 ± 291.40 mL/min, p=0.048).",Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055553/),[ml] / [min],699.13,247523,DB00331,Metformin
,21973270,AUC,"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),[h·mg] / [l],21,250343,DB00331,Metformin
,21973270,C(max),"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),[mg] / [l],3,250344,DB00331,Metformin
,21973270,t(max),"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),h,2.5,250345,DB00331,Metformin
,21973270,t(,"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),h,4,250346,DB00331,Metformin
,21973270,V(d),"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),l,111,250347,DB00331,Metformin
,21973270,CL,"Metformin concentration-time curves were similar in girls receiving similar metformin doses (range 21-29 mg/kg): in those girls, the mean AUC was 21 mg · h/L, with a C(max) of 3 mg/L, t(max) of 2.5 hours, t(&frac12;) of 4 hours, V(d) of 111 L and CL of 20 L/h.",Pharmacokinetics of metformin in girls aged 9 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973270/),[l] / [h],20,250348,DB00331,Metformin
more,18401776,retention time,"In order to avoid this variability, efforts have been made to increase the retention time of the drug delivery systems for more than 12 hours utilizing floating or hydrodynamically controlled drug delivery systems.","Cellulose acetate microspheres as floating depot systems to increase gastric retention of antidiabetic drug: formulation, characterization and in vitro-in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401776/),h,12,252316,DB00331,Metformin
,18401776,en,Spherical and smooth-surfaced microspheres with encapsulation efficiency ranging from 73% to 98% were obtained.,"Cellulose acetate microspheres as floating depot systems to increase gastric retention of antidiabetic drug: formulation, characterization and in vitro-in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401776/),%,73,252317,DB00331,Metformin
,18401776,en,Spherical and smooth-surfaced microspheres with encapsulation efficiency ranging from 73% to 98% were obtained.,"Cellulose acetate microspheres as floating depot systems to increase gastric retention of antidiabetic drug: formulation, characterization and in vitro-in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401776/),%,98,252318,DB00331,Metformin
,11402634,bioavailability,"The mean bioavailability from each gastric-retentive tablet was approximately 115%, relative to the immediate-release (IR) product.",Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402634/),%,115,253379,DB00331,Metformin
,25573751,area under the concentration-time curve (AUC)0-∞,There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[h·μg] / [l],19.7,254456,DB00331,Metformin
,25573751,area under the concentration-time curve (AUC)0-∞,There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[h·μg] / [l],14.3,254457,DB00331,Metformin
,25573751,renal clearance (CLr),There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[l] / [h],16.8,254458,DB00331,Metformin
,25573751,renal clearance (CLr),There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[l] / [h],34.1,254459,DB00331,Metformin
,25573751,tubular secretion clearance (CLt),There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[l] / [h],8.1,254460,DB00331,Metformin
,25573751,tubular secretion clearance (CLt),There were also differences in the pharmacokinetic parameters (95 % confidence interval) of metformin between these two groups [area under the concentration-time curve (AUC)0-∞ 19.7 (15.7-23.8) vs. 14.3 (11.7-16.9) μg h/L; renal clearance (CLr) 16.8 (8.5-25.0) vs. 34.1 (24.9-43.2) L/h; tubular secretion clearance (CLt) 8.1 (2.2-18.1) vs. 22.7 (15.5-29.8) L/h; all P < 0.05].,Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573751/),[l] / [h],22.7,254461,DB00331,Metformin
,21538144,t(½),"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),h,3.8,254487,DB00331,Metformin
,21538144,t(max),"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),h,2.0,254488,DB00331,Metformin
,21538144,C(max),"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),[mg] / [l],1.4,254489,DB00331,Metformin
,21538144,C(mean),"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),[mg] / [l],0.5,254490,DB00331,Metformin
,21538144,AUC(0-12),"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),[h·mg] / [l],6.4,254491,DB00331,Metformin
,21538144,Cl/f,"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),[l] / [h],105,254492,DB00331,Metformin
,21538144,Vd/f,"Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%.",Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),l,551,254493,DB00331,Metformin
,21538144,plasma concentration ratios,Umbilical/maternal metformin plasma concentration ratios were 0.7 (0.4-1.3).,Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),,0.7,254494,DB00331,Metformin
,21538144,plasma concentrations ratios,Caution is warranted as umbilical/maternal metformin plasma concentrations ratios of around 0.7 require metformin dosage adjustment.,Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538144/),,0.7,254495,DB00331,Metformin
,33901756,flow rate,A mobile phase of formic acid (0.01 %): acetonitrile (70:30 v/v) with a flow rate of 0.3 mL/min achieved optimum separation.,Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33901756/),[ml] / [min],0.3,255495,DB00331,Metformin
t exceed,33901756,run time,The run time of the proposed Method didn't exceed 3.0 min allowing faster analysis and determination of larger number of samples per day without affecting accuracy and sensitivity.,Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33901756/),min,3.0,255496,DB00331,Metformin
,21810918,terminal half-life,"At dose levels or more than 5 mg/kg, dalotuzumab mean terminal half-life was 95 hours or more, mean C(min) was more than 25 μg/mL, clearance was constant, and serum exposures were approximately dose proportional.","A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21810918/),h·more·or,95,258391,DB00331,Metformin
more,21810918,C(min),"At dose levels or more than 5 mg/kg, dalotuzumab mean terminal half-life was 95 hours or more, mean C(min) was more than 25 μg/mL, clearance was constant, and serum exposures were approximately dose proportional.","A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21810918/),[μg] / [ml],25,258392,DB00331,Metformin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,260.2,258990,DB00331,Metformin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,183.0,258991,DB00331,Metformin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,390.2,258992,DB00331,Metformin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,268.2,258993,DB00331,Metformin
higher,31384829,recoveries,All obtained recoveries were higher than 90.0% while the accuracy was in the range of 88.14-113.05% and the relative standard deviation was below 10.0% for all investigated drugs by the proposed method.,Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),%,90.0,258994,DB00331,Metformin
more,31003498,IC50,"Single treatment of RGE did not inhibit the in vitro transport activity of OCT1/2 up to 500 µg/mL and inhibited MATE1/2-K with high IC50 value (more than 147.8 µg/mL), suggesting that concomitant used of RGE did not directly inhibit OCT- and MATE-mediated metformin uptake.",Enhanced Intestinal Permeability and Plasma Concentration of Metformin in Rats by the Repeated Administration of Red Ginseng Extract. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003498/),[μg] / [ml],147.8,259821,DB00331,Metformin
,31980499,arterial-to-venous plasma concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.0,261577,DB00331,Metformin
,31980499,venous umbilical cord-to-maternal concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.4,261578,DB00331,Metformin
,31980499,arterial umbilical cord-to-maternal concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.5,261579,DB00331,Metformin
,23475568,maximum daily doses,"Dosing simulations revealed that the maximum daily doses in relation to creatinine clearance to prescribe to patients are 500 mg (15 ml/min), 1,000 mg (30 ml/min), 2,000 mg (60 ml/min) and 3,000 mg (120 ml/min), for both the IR and XR formulations.",Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23475568/),,60,263473,DB00331,Metformin
,12746638,clearance,"ARF, although mild, decreased renal MET clearance (0.29 +/- 0.05 vs 1.01 +/- 0.31 ml/min/100 g, P<0.05) and increased plasma and renal tissue MET levels (x 2-4).",Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746638/),[ml] / [100·g·min],0.29,264931,DB00331,Metformin
,12746638,clearance,"ARF, although mild, decreased renal MET clearance (0.29 +/- 0.05 vs 1.01 +/- 0.31 ml/min/100 g, P<0.05) and increased plasma and renal tissue MET levels (x 2-4).",Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746638/),[ml] / [100·g·min],1.01,264932,DB00331,Metformin
,31575298,flow rate,"Separation was done by pumping isocratic mobile phase consisting of methanol and 10 mM ammonium trifluoroacetate (90:10, v/v) in positive ion mode at a flow rate of 0.8 mL/min.",Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),[ml] / [min],0.8,266414,DB00331,Metformin
,31575298,m,"Turbo ion spray ionization was used for mass transition of m/z 468.070/355.100 and m/z 130.072/71.200 for empagliflozin and metformin, respectively.",Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),,468.070,266415,DB00331,Metformin
,31575298,m/z,"Turbo ion spray ionization was used for mass transition of m/z 468.070/355.100 and m/z 130.072/71.200 for empagliflozin and metformin, respectively.",Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),,130.072,266416,DB00331,Metformin
,31575298,m/z,"Turbo ion spray ionization was used for mass transition of m/z 468.070/355.100 and m/z 130.072/71.200 for empagliflozin and metformin, respectively.",Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),,71.200,266417,DB00331,Metformin
,31575298,limit of q,The limit of quantification was found to be 10.09 ng/mL for empagliflozin and 25.44 ng/mL for metformin.,Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),[ng] / [ml],10.09,266418,DB00331,Metformin
,31575298,limit of q,The limit of quantification was found to be 10.09 ng/mL for empagliflozin and 25.44 ng/mL for metformin.,Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),[ng] / [ml],25.44,266419,DB00331,Metformin
,31575298,run time,A short run time of 3.3 min allows analysis of more than 400 plasma samples per day.,Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31575298/),min,3.3,266420,DB00331,Metformin
,10376904,terminal phase half-life,Disposition of the drug was characterized by a three-compartment model with a terminal phase half-life of (mean +/- SD) 11.5+/-4.2 hours.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),h,11.5,266864,DB00331,Metformin
,10376904,central compartment,Metformin was distributed to a small central compartment of 0.057+/-0.017 L/kg and to 2 peripheral compartments with volumes of distribution of 0.12+/-0.02 and 0.37+/-0.38 L/kg.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [kg],0.057,266865,DB00331,Metformin
,10376904,volumes of distribution,Metformin was distributed to a small central compartment of 0.057+/-0.017 L/kg and to 2 peripheral compartments with volumes of distribution of 0.12+/-0.02 and 0.37+/-0.38 L/kg.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [kg],0.12,266866,DB00331,Metformin
,10376904,volumes of distribution,Metformin was distributed to a small central compartment of 0.057+/-0.017 L/kg and to 2 peripheral compartments with volumes of distribution of 0.12+/-0.02 and 0.37+/-0.38 L/kg.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [kg],0.37,266867,DB00331,Metformin
,10376904,Steady-state volume of distribution,Steady-state volume of distribution was 0.55+/-0.38 L/kg.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [kg],0.55,266868,DB00331,Metformin
,10376904,renal clearance,"After IV administration, 84+/-14% of the dose was excreted unchanged in urine, with renal clearance of 0.13+/-0.03 L/h/kg; nonrenal clearance was negligible (0.02+/-0.02 L/kg).",Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [h·kg],0.13,266869,DB00331,Metformin
,10376904,nonrenal clearance,"After IV administration, 84+/-14% of the dose was excreted unchanged in urine, with renal clearance of 0.13+/-0.03 L/h/kg; nonrenal clearance was negligible (0.02+/-0.02 L/kg).",Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),[l] / [kg],0.02,266870,DB00331,Metformin
,10376904,bioavailability,Mean bioavailability of orally administered metformin was 48%.,Pharmacokinetics of the antihyperglycemic agent metformin in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10376904/),%,48,266871,DB00331,Metformin
>,30102470,payload capacity,"PA, a hydrophobic counterion, increases the hydrophobicity of MET and TPT and facilitates MSNs with exceptionally high payload capacity (>40 and 32 wt%, respectively) and controlled release profile.",Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30102470/),,40,267216,DB00331,Metformin
>,30102470,payload capacity,"PA, a hydrophobic counterion, increases the hydrophobicity of MET and TPT and facilitates MSNs with exceptionally high payload capacity (>40 and 32 wt%, respectively) and controlled release profile.",Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30102470/),,32,267217,DB00331,Metformin
,25240532,half-life,"The mean half-life ranged from 17 to 26 days, and mean systemic clearance ranged from 0.094 to 0.128 mL/h/kg.",Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25240532/),d,17 to 26,270693,DB00331,Metformin
,25240532,systemic clearance,"The mean half-life ranged from 17 to 26 days, and mean systemic clearance ranged from 0.094 to 0.128 mL/h/kg.",Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25240532/),[ml] / [h·kg],0.094 to 0.128,270694,DB00331,Metformin
,32989831,IC50,"In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC50 values of 14.7, 0.340, and 0.135 µM, respectively.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),μM,14.7,271390,DB00331,Metformin
,32989831,IC50,"In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC50 values of 14.7, 0.340, and 0.135 µM, respectively.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),μM,0.340,271391,DB00331,Metformin
,32989831,IC50,"In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC50 values of 14.7, 0.340, and 0.135 µM, respectively.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),μM,0.135,271392,DB00331,Metformin
,32989831,IC50,"Tucatinib also inhibited OCT2- and MATE1-mediated transport of creatinine, with IC50 values of 0.107 and 0.0855 µM, respectively.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),μM,0.107,271393,DB00331,Metformin
,32989831,IC50,"Tucatinib also inhibited OCT2- and MATE1-mediated transport of creatinine, with IC50 values of 0.107 and 0.0855 µM, respectively.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),μM,0.0855,271394,DB00331,Metformin
,32989831,renal clearance,"Metformin exposure increased (1.4-fold) and renal clearance decreased (29.99-17.64 L/h) with tucatinib, with no effect on metformin maximum concentration.",Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32989831/),[l] / [h],29.99-17.64,271395,DB00331,Metformin
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271646,DB00331,Metformin
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271647,DB00331,Metformin
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271648,DB00331,Metformin
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271649,DB00331,Metformin
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],231,271650,DB00331,Metformin
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],135,271651,DB00331,Metformin
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],225,271652,DB00331,Metformin
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],141,271653,DB00331,Metformin
,30203123,accumulation ratios,"RN909 dose-normalized AUCinf increased more than dose-proportionally following single SC doses, and after multiple doses, accumulation ratios ranged from 1.3 to 3.4.","Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203123/),,1.3 to 3.4,272683,DB00331,Metformin
,26114554,AUC(0-24),"After oral administration, the AUC(0-24), t(1/2) and t(max) of the prepared beads were of 246.74 ± 26.81 mg, 11.84 ± 2.79 and 7.17 ± 1.75 h, respectively, demonstrating its bioequivalence to the marketed products.","Formulation, physicochemical characterization and in-vivo evaluation of ion-sensitive metformin loaded-biopolymeric beads. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114554/),mg,246.74,272751,DB00331,Metformin
,26114554,t(1/2),"After oral administration, the AUC(0-24), t(1/2) and t(max) of the prepared beads were of 246.74 ± 26.81 mg, 11.84 ± 2.79 and 7.17 ± 1.75 h, respectively, demonstrating its bioequivalence to the marketed products.","Formulation, physicochemical characterization and in-vivo evaluation of ion-sensitive metformin loaded-biopolymeric beads. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114554/),h,11.84,272752,DB00331,Metformin
,26114554,t(max),"After oral administration, the AUC(0-24), t(1/2) and t(max) of the prepared beads were of 246.74 ± 26.81 mg, 11.84 ± 2.79 and 7.17 ± 1.75 h, respectively, demonstrating its bioequivalence to the marketed products.","Formulation, physicochemical characterization and in-vivo evaluation of ion-sensitive metformin loaded-biopolymeric beads. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114554/),h,7.17,272753,DB00331,Metformin
